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           This dissertation describes the single cell metabolomics analysis and microscale 
extracellular metabolites analysis using the Single-probe mass spectrometry (MS) 
techniques.  
            Chapter one summarizes the current technique for single cell analysis, including 
the exploration of single cell genome, transtriptome, proteome, and metabolome. 
Techniques used for extracellular metabolites analysis were also briefly described.  
            Chapter two introduces the metabolomic analysis of single cancer stem cells 
(CSCs) using the Single-probe MS technique. CSCs are rare types of cells responsible for 
tumor development, relapse, and metastasis. However, current research in CSC biology is 
largely limited by the difficulty of obtaining sufficient CSCs. Single-cell analysis 
techniques are promising tools for CSC-related studies. The Single-probe MS technique 
was used to investigate the metabolic features of live colorectal CSCs at the single-cell 
level. Experimental data were analyzed using statistical analysis methods, including the t-
test and partial least squares discriminant analysis. The overall metabolic profiles of 
CSCs are distinct from non-stem cancer cells (NSCCs). Specifically, tricarboxylic acid 
(TCA) cycle metabolites are more abundant in CSCs compared to NSCCs, indicating 
their major energy production pathways are different. Moreover, CSCs have relatively 
higher levels of unsaturated lipids. Inhibiting the activities of stearoyl-CoA desaturase-1 
(SCD1), nuclear factor κB (NF-κB), and aldehyde dehydrogenases (ALDH1A1) in CSCs 
significantly reduced the abundances of unsaturated lipids and hindered the formation of 
spheroids, resulting in reduced stemness of CSCs. Our techniques and experimental 
protocols can be potentially used for metabolomic studies of other CSCs and rare types of 
	 xiii	
cells and provide a new approach to discovering functional biomarkers as therapeutic 
targets. 
        Chapter three demonstrates the investigation of metabolic features of single algae 
cells under different environment stress. Traditional approaches for the assessment of 
physiological responses of microbes in the environment rely on bulk filtration techniques 
that obscure differences among populations as well as among individual cells. The 
Single-probe MS technique was used to directly extract metabolites from living, 
individual phytoplankton cells for analysis. Marine dinoflagellate Scrippsiella trochoidea 
cells were grown under different illumination levels and under nitrogen (N) limiting 
conditions. In both experiments, significant differences in the cellular metabolome of 
individual cells could readily be identified, though the vast majority of detected 
metabolites could not be assigned to KEGG pathways. Using the same approach, 
significant changes in cellular lipid complements were observed, with individual lipids 
being both up- and down-regulated under light vs. dark conditions. Conversely, lipid 
content increased across the board under N limitation, consistent with an adjustment of 
Redfield stoichiometry to reflect higher C:N and C:P ratios. Overall, these data suggest 
that the Single-probe MS technique has the potential to allow for near in situ 
metabolomic analysis of individual phytoplankton cells, opening the door to targeted 
analyses that minimize cell manipulation and sampling artifacts, while preserving 
metabolic variability at the cellular level. 
Chapter four describes comprehensive studies of early-stage drug resistance cells using 
single cell MS metabolomics combined with other techniques. Efficacy of chemotherapy 
is often limited by de novo or acquired drug resistance in clinic treatment. Studying the 
	 xiv	
underlying mechanisms of drug resistance is necessary for better development of novel 
therapeutic strategies. Studies in this field are generally conducted through bulk analysis 
of samples obtained from long-term chemotherapy. Investigating the metabolic changes 
occurred in the early-stage of drug resistance at the single-cell level provides insights into 
drug resistant mechanisms, and the developed techniques can be potentially used for 
early monitoring of drug resistance in clinic. Comprehensive studies were carried out 
using multiple techniques, including single cell MS metabolomics, western blotting, flow 
cytometry, and reverse transcription polymerase chain reaction (RT-PCR), to explore 
mechanisms of irinotecan resistance at the initial stage at the single cell level. Results 
illustrate that SCD1 is upregulated in the irinotecan-resistant cells, which show increased 
levels of stemness and decreased degrees of ROS. 
Chapter 5 demonstrates the critical roles of extracellular compounds in 
intercellular communication, tumor proliferation, and cancer cell metastasis. However, 
the lack of appropriate techniques leads to limited studies of extracellular metabolite. 
Here, we introduced a microscale collection device, the Micro-funnel, fabricated from 
biocompatible fused silica capillary. With a small probe size (∼25 µm), the Micro-funnel 
can be implanted into live multicellular tumor spheroids to accumulate the extracellular 
metabolites produced by cancer cells. Metabolites collected in the Micro-funnel device 
were thenextracted by a microscale sampling and ionization device, the Single-probe, for 
real-time mass spectrometry (MS) analysis. We successfully detected the abundance 
change of anticancer drug irinotecan and its metabolites inside spheroids treated under a 
series of conditions. Moreover, we found that irinotecan treatment dramatically altered 
the composition of extracellular compounds. Specifically, we observed the increased 
	 xv	
abundances of a large number of lipids, which are potentially related to the drug 
resistance of cancer cells. This study provides a novel way to detect the extracellular 
compounds inside live spheroids, and the successful development of our technique can 
benefit the research in multiple areas, including the microenvironment inside live tissues, 



















Chapter 1.   Introduction 
 
1.1 Background 
            A single cell is the basic functional biological unit, and cellular status and 
molecular compositions can vary based on different external influence and internal 
process. To study cellular functional and structural roles in bioanalytical system, many 
traditional bioanalytical methods rely on a bulk analysis, providing the averaged results 
from the analyzed specimen. In many cases it is suitable to conduct the traditional bulk 
analysis for samples with adequate amounts. However, there is an increasing need to 
study extremely limited amounts of samples requiring measurements to be performed at 
the single-cell or even subcellular level.[1-3] For example, the rare cells such as 
circulating tumor cells (CTC) have limited populations, and one of the biggest challenges 
in CTCs’ studies is to obtain sufficient cells.[4, 5] Therefore, techniques performing 
meaningful biological research from individual cells would provide a great advantage for 
the study of CTCs.[6, 7] Single-cell analysis allows us to study the individual cells with 
limited population, and investigate the heterogeneity of similar cells, which further 
promote the development of the understanding of cellular physiological phenomena and 
fundamental biology. In addition, single cell analysis is an important step to facilitate the 
investigation of cellular and subcellular genomics, transcriptomics, proteomics, and 
metabolomics.[2] 
1.2 Techniques for single cell intracellular analysis 
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            The advancement in bioanalytical techniques provide the opportunity to 
investigate complex biological systems from individual cells. Analysis of genome, 
transcriptome, proteome, and metabolome at the single-cell level promotes system 
biological study of gene-expression dynamics, cell heterogeneity and disease 
pathogenesis.[2, 8] Moreover, advanced single cell analysis techniques provide novel and 
significant insight into studies of biology, medicine, toxicology, and clinical pathology. 
1.2.1 Challenges in single cell studies 
            Despite the significant advance, single cell analysis has been considered as a 
challenge task. The major challenge for single cell analysis is the extremely limited 
amount of cellular contents with very complex compositions available from a single cell. 
In addition, intracellular molecules present as wide ranges of concentrations.[9, 10] Thus, 
it is obligatory that techniques for single cell analysis need to have high spatial resolution, 
detection sensitivity, molecular selectivity, and reliability.[11]  
1.2.2 Single cell genomics and transcriptomics analysis 
             Recent advancement of sequencing technique allows us to detect genome, 
transcriptome, and epigenome at the single-cell level to investigate the cell heterogeneity 
and status. Figure1.1 presents the development of single cell sequencing.[2] The PCR 
method permits the analysis of DNA in single cell, and developments of whole genome 
amplification (WGA)[12, 13] and whole transcriptome amplification (WTA)[14]  
promote the quantitative analysis of DNA and RNA in individual cells. Later, the 
genome-wide analysis of DNA and RNA has been realized by the invention of next 
generation sequencing, and several methods have been further applied to study the single 
cell DNA methylation and proteome analysis.[15] With the ability to detect both genome 
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and transcriptome from the same single cell, multi-omics profile for the same cell could 
be performed.[16] The integrated analysis of the genome and transcriptome promotes the 
study of regulatory variation[17], DNA structural alteration[18], and RNA editing[19]. In 
order to perform the integrated analysis at the single cell level, several methods have 
been applied to separate RNA from genomic DNAs.[8, 20-23]  
 
Figure 1.1   Development timeline of single cell sequencing methods. 
 
            Han et al. developed the microfluidic platform to achieve cell lysate, separation, 
and amplification of gDNA and cytoplasmic mRNA on a chip. DNA and RNA will be 
further detected using on-chip PCR, gel electrophoresis, and Sanger sequencing.[21] This 
is the first measurement of genome and transcripts from single cells. Microfluidic device 
designed for single cell analysis based on separate extraction process, while later several 
techniques have been developed to extract genome and transcript in parallel.[22-25] 
Parallel extraction minimizes sample preparation steps to reduce the sample loss and 
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contamination compared to separate extraction. GDNA-mRNA sequencing (DR-seq)[23] 
and genome and transcriptome sequencing (G&T-seq)[26] are developed to perform 
simultaneously analysis DNA and cytoplasmic RNA without separating nucleus and 
cytoplasm.  Based on the technique of G&T-seq, single-cell methylation and 
transcriptome sequencing (scM&T-seq) methods were developed to detect the 
methylation and transcriptome expression level.[27] In addition, more techniques have 
been reported to study single cell epigenomics such as transposase-accessible chromatin 
sequencing (ATAC-seq)[28] and single-cell DNase sequencing (scDNase-seq).[29] These 
techniques allow new co-measurement of single cell epigenomics and transcriptomics in 
the future.  
1.2.3 Single cell protein analysis 
            Techniques for single cell DNA and RNA analysis provide the information on the 
gene-products level, but they are incapable to study the expression, post-translational 
modification, and interactions of proteins in single cells. Recent advancements in 
microscopy, flow cytometry, microfluidics, and mass spectrometry allow the detection of 
proteins at the single-cell level.[30, 31] Fluorescent flow cytometry is a well-established 
technique for single-cell surface protein analysis. This technique utilizes single cells, 
which are stained with up to 10-15 specific fluorescent-labeled antibodies, and flows 
them through a capillary tube to be detected by photomultiplier tubes[32, 33]. Fluorescent 
flow cytometry is able to semi-quantify multiple proteins in single cells related to a 
variety of disease.[34] However, traditional flow cytometry normally requires a large of 
amount of cells to be processed, and therefore, it is not suitable for the analysis of cells 
with limited numbers such as CTCs. In order to overcome the limitation, microfluidic 
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flow cytometry has been developed to study the cells with limited numbers (10-100).[35] 
Moreover, the microfluidic flow cytometry also make it possible to study protein in a 
single cell with two orthogonal methods: imaging and cytometry.[1, 36-38] As show in 
Figure 1.2, a parallel microfluidic flow cytometry has been developed to perform cell 
culture and cell preparation combined with fluorescence microscope and microfluidic 
flow cytometer to investigate the immune response.[39]  
 
Figure 1.2. A parallel microfluidic flow cytometer for single cell protein screening. (a)	
Cells are loaded into the phosphoflow chip (pFC) by pressure-driven flow.	(b) pFC 
phosphorylation assay in incubation chambers proceeds as (1) cell culture and infection, 
(2) phospho-profiling, (c) imaging, and (d) flow cytometry.  
[Reprinted with the permission from Srivastava, Nimisha, et al., Analytical Chemistry 
81.9 (2009): 3261-3269.	Copyright © 2009, American Chemical Society] 
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            Besides flow cytometry, single cell western blot has been developed to study 
single cell proteins.[40] Single cell western blot targets specific proteins by coupling 
antibody based detection and sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) separation as shown in Figure 1.3. [41] Antibody based methods provide 
the golden standard method in protein analysis at single cell level. However, these 
technique cannot simultaneously analyze more than 20 proteins, limiting the study of 
system-level biological pathways that requires multiple correlation measurements.[30]  
Single cell mass spectrometry allows the detection of whole proteome 
simultaneously at single cell level. [42] With the advantage of label-free and high 
sensitivity, mass spectrometry technique has the potential to quantify entire proteome in a 
single cell. [30] 
 
Figure 1.3. Single cell western blotting workflow. (a) Thousands of microwells patterned 
in a photoactive polyacrylamide gel seated on a glass slide. (b) Fluorescent microspheres 
are blocked in a microwell. (c) Open-gel single cell western analysis including cell 
setting and cell lysis. (d) PAGE separates five fluorescently labeled proteins. (e) Single 
cell western detects proteins from a single cell. 
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[Reprinted with the permission from Hughes, Alex J., et al., Nature Methods 11.7 (2014): 
749.	Copyright © 2014, Springer Nature] 
 
1.2.3 Single cell metabolomics analysis 
            Compared to results obtained from single cell analysis of genomics, 
transcriptomics, and proteomics, single cell metabolomics presents more immediate and 
dynamic status of a single cells. Metabolites are directly related to a variety of biological 
mechanisms, and they are regarded as indicators of phenotypic heterogeneity.[43] 
Analysis of metabolites in individual cells is challenging, because metabolites changed 
rapidly and the cellular contents are very complex. Therefore, high selectivity and 
sensitivity are needed for analytical techniques to perform single cell metabolomics 
analysis. Currently, many analytical techniques, including capillary electrophoresis, 
Raman spectroscopy, microfluidics, and mass spectrometry (MS), have been applied to 
study the metabolites at single cell level.[44-49] Among them, MS is becoming a 
powerful method and playing an important role in single cell analysis due to its 
outstanding properties of high sensitivity, high resolution, and label-free detection.[49]  
            According to the sample ionization environment, there are two major groups of 
MS based techniques for single cell metabolomics analysis: vacuum-based and ambient-
based MS techniques.[50, 51] Secondary ion mass spectrometry (SIMS) [52] and matrix-
assisted laser desorption ionization (MALDI)[53, 54] are dominant vacuum-based MS 
techniques, and they provide important advancements in bioanalytical method 
development. For example, MALDI desorbs and ionizes the metabolites by incorporating 
the metabolites into a suitable matrix. With an excellent spatial resolution (~5 µm), 
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MALDI is becoming the dominant approaches for single cell analysis (Figure 1.4).[53] 
However, vacuum-based MS techniques still have their drawbacks, such as obligatory 
sample preparation and high vacuum conditions, limiting the studies of live cells.  
 
Figure 1.4. Single cell MALDI-MS analysis. Single cells are mixed with matrix and 
subjected to MALDI-MS measurement of metabolites. 
[Reprinted with the permission from Amantonico, Andrea, et al., Analytical Chemistry 
82.17 (2010): 7394-7400.	Copyright © 2010, American Chemical Society] 
 
            With the development of ambient sampling and ionization techniques, ambient-
based MS has been used to perform live single cell analysis with minimal preparation, 
which offers direct, rapid, in vivo investigation of the heterogeneity of individual 
cells.[50] Live single-cell video-mass spectrometry utilizes the gold-coated nanospray tip 
to insert into a single cell under a video microscope, and the cellular metabolites are 
sucked into the tip acting as a micropipette. Then the nanospray tip is directly coupled 
with MS for the detection of the cellular metabolites (Figure 1.5). Hundreds of small 
molecules can be detected by the live single-cell video-mass spectrometry.[55] 
Microprobe single-cell capillary electrophoresis electrospray ionization mass 
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spectrometry (CE-ESI-MS) technique integrates micro sampling, microscale extraction, 
and CE-MS to investigate the metabolic feature of single embryonic cells (Figure 1.6).[56, 
57] Particularly, with the exquisite separation efficiency, microprobe single-cell CE-ESI 
MS could address the complex metabolome to offer complementary advantages for 
single-cell studies.[56]  
 
 
Figure 1.5. Live single-cell video mass spectrometry. The analysis process has two steps. 
In the first step, video microscope is used to monitor single cells, and cellular contents 
are directly sucked into a nanospray ionization tip, which is transferred to a mass 
spectrometer.	A voltage is then applied to start the nanospray. In the second step, MS 
spectra are exported and data analysis is performed to extract key metabolites. Some 
targeted MS peaks were subjected to MS/MS analysis for identification. 
[Reprinted with the permission from Mizuno, Hajime, et al., Journal of Mass 




Figure 1.6. Microprobe single-cell CE-ESI-MS for metabolomic analysis of singe live 
embryos. (1) The status of single cells is monitored using a stereomicroscope. (2) 
Cellular content are sucked into a pulled capillary. (3) A multiaxis translation stage 
coupled with (4) a microinjector and (5) a delivering vacuum. (6) The enriched cell 
contents are injected into a tube for extraction. (7) The extracted metabolites are 
measured by a microloading CE platform. (8) CE platform is connected to an ESI source. 
(9) Metabolites are ionized for detection using a high-resolution tandem mass 
spectrometer. (10) Metabolites peaks detected by MS. 
[Reprinted with the permission Onjiko, Rosemary M., et al., Analytical Chemistry 89.13 
(2017): 7069-7076. Copyright © 2017, American Chemical Society] 
 
            The Single-probe MS is another single-cell ambient MS method. The Single-
probe is a miniaturized multifunctional sampling and ionization device that can be 
coupled with MS for the real-time single cell analysis.[48, 58, 59] This device is 
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composed of dual-bore quartz tubing pulled by a laser pipette puller, a fused silica 
capillary, and a nano-ESI emitter. With an extremely small sampling probe size (<10 µm), 
the Single-probe cab be inserted into single cells to efficiently extract cellular contents 
for ionization and MS analysis (Figure 1.7).[48]  
 
Figure 1.7. The Single-probe MS system. (a)	Fabrication	of	Single-probe. (b) 
Photograph of a Single-probe. (C) Calibrated microscopic photo of a Single-probe tip. (D) 
Single cell MS analysis setup. 
[Reprinted with the permission Pan, Ning, et al., Analytical Chemistry 86.19 (2014): 
9376-9380. Copyright © 2014, American Chemical Society] 
 
             In general, single cell analysis promotes the understanding of cell function and 
heterogeneity based on genome, transcriptome, proteome and metabolome study 
abstained at single cell level. Single cell multi-omics analysis will allow us to explore the 
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correlation and mechanism of cell genetic variation and expression dynamics of proteins 
and metabolites, enabling more detailed investigation of cellular status in multiple 
diseases.[22, 60]  
1.3. Microscale analysis of extracellular metabolites  
In addition to intracellular analysis, previous studies indicate that microenvironment is 
essential for biological function of tumors, including cell−cell communication and cancer 
cell migration and metastasis.[61] Investigation of extracellular compounds produced by 
tumor cells enable us to potentially discover specific cancer biomarkers, and provide 
guidelines for the amelioration of current cancer therapies. However, studies of 
extracellular metabolites have not been widely performed due to the lack of appropriate 
analytical techniques.[62, 63] In a long time, the detection of extracellular biomolecules 
is limited by their low concentrations and loss through diffusion into cell culture medium. 
Microdialysis technique utilizes microdialysis probes that contain semipermeable 
membranes to enrich extracellular molecules. However, the general sizes of microdialysis 
probe range between 200 and 500 µm, resulting in limited spatial resolution and studies 
of small tumors.[64-66] Micro-funnel device with small tip size (∼25 µm) has been 
developed to study extracellular molecules in multicellular spheroids. Micro-funnel can 
be implanted into a live spheroid for direct collection of extracellular compounds without 
being diluted and selected. Micro-funnel can be coupled with the Single-probe MS to 
monitor extracellular drug and metabolites inside live spheroids for real-time analysis 
(Figure 1.8).[59] In general, the development of extracellular components detection 
technique can benefit the research in multiple areas, including the microenvironment 
inside live tissues, cell−cell communication, biomarker discovery, and drug development. 
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Figure 1.8   The Micro-funnel coupled with the Single-probe MS analysis for 
extracellular compounds detection in live spheroids. 
[Reprinted with the permission Sun, Mei, et al., Analytical Chemistry 89.17 (2017): 
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Chapter 2.    Metabolomic Studies of Live Single Cancer Stem Cells  
Using Mass Spectrometry 
 
2.1 Introduction 
          Cancer is one of the most common causes of death, and it threats the health of 
millions of people.[1] Cancer therapy is suffered from drug resistance, which leads to 
tumor recurrence and metastasis.[2] Cancer stem cells (CSCs) are a rare subset of cancer 
cells possessing the ability to self-renew and initiate tumors.[3] Recent studies indicate 
that CSCs are the main source of therapy resistance, and they are responsible for tumor 
recurrence and metastasis.[4] In particular, the heterogeneity of CSCs forcefully impedes 
anti-cancer therapies.[5] Unfortunately, the current understanding of the characters of 
CSCs and their roles in drug resistance is largely lacked, hindering the development of 
novel tumor diagnostic and therapeutic strategies. 
          One of the biggest challenges in CSC studies is to obtain sufficient cells, especially 
from patients, for analysis.[6] However, traditional approaches to studying cell 
metabolomics, such as HPLC/MS, typically require a large number of cells for sample 
preparation.[7] Therefore, techniques performing meaningful biological research from 
individual cells would provide a great advantage for the study of CSCs.[8] A number of 
single-cell analysis techniques, such as single-cell sorting and single-cell sequencing, 
have been developed to effectively utilize the limited resources of CSCs.[9, 10] As the 
final downstream products, metabolites reflect gene regulation, pathway interactions, and 
environmental perturbations, and they directly indicate cell status. Therefore, the single 
cell metabolomics study, particularly based on live single cells, can truly provide 
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chemical information of individual cells to effectively investigate their biological 
phenotypes.[11, 12] Due to its high detection sensitivity and broad range of molecular 
analysis, mass spectrometry (MS) has become a predominant technique for metabolomics 
research. However, the single cell MS (SCMS) analysis of single CSCs has been rarely 
performed. To the best of our knowledge, only one MS-based metabolomics study of 
single CSCs has been reported[13], in which the time-of-flight secondary ion mass 
spectrometry (TOF-SIMS) has been utilized. Due to complex background at low mass 
range and high degree of ion fragmentation, only a few molecules were identified. In 
addition, because cell metabolites can rapidly change upon the alteration of cell living 
environment[14, 15], any method requiring a vacuum environment (e.g., for sampling 
and ionization) and nontrivial sample preparation, such as SIMS and MALDI (Matrix 
Assisted Laser Desorption/Ionization), precludes the capability of obtaining molecular 
information from live cells. Thus, metabolomics of live single CSCs is largely 
unexplored.[16] Current methods used to detect the CSCs are mainly based on a number 
of common cell surface biomarkers, such as CD133, CD24, CD44, and the activity of 
aldehyde dehydrogenase (ALDH1).[17] Because CSCs are highly heterogeneous, using 
novel techniques to discover new candidates for CSC markers will provide additional 
approaches to identify target CSCs.[18] Moreover, many CSCs markers are selected 
without knowing their functional roles, leading to limited reliability as biomarkers.[19] 
Therefore, characteristic molecules identified using SCMS techniques can be potentially 
used as novel function-based biomarkers of CSCs. 
          Colorectal cancer (CRC) is the fourth leading cause of cancer-related death, and 
CSCs play a critical role in tumor relapse and metastasis[20]; however, the metabolomic 
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characteristics of colon CSCs in their living status are largely unknown. In this study, we 
used live CSCs derived from the HCT-116 (colorectal cancer) cells as the model system, 
and conducted metabolomic analysis at single cell level. In the comparison study, we 
utilized the regular HCT-116 as the model of non-stem cancer cells (NSCCs) to illustrate 
the metabolic differences between CSCs and NSCCs. All SCMS experiments were 
conducted using the Single-probe MS techniques (Figures 2.1A and 2.1B), which have 
been previously applied in live single cell analysis[21-24], mass spectrometry imaging of 
tissues[25], and metabolomic analysis of extracellular molecules in live multicellular 
spheroids.[26] 
 
2.2 Experimental Section 
2.2.1 Cell lines and cell culture 
          Enriched human colon cancer HCT-116 CSCs were purchased from ProMab 
Biotechnology (Richmond, CA), and HCT-116 cancer cells (NSCCs) were originally 
obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). The 
HCT-116 CSCs were cultured in Cancer Stem Premium™ medium (Probmab 
Biotechnology) to maintain their stemness (Figure 2.1C)[27], and the passage number of 
cells was limited within three to maintain the population of CSCs during cell culture. The 
HCT-116 NSCCs were cultured in McCoy’s 5A cell culture medium containing 10% FBS 
(fetal bovine serum) and 1% Pen Strep (Life Technologies, Grand Island, NY, USA). All 
cells were cultured at 37°C in an incubator with 5% CO2 supply (HeraCell, Heraeus, 
Germany). 
2.2.2 Reagents for the treatment of CSCs 
	 26	
          CAY10566 (SCD1 inhibitor, ≥98%), dimethylaminoparthenolide DMAPT (NF-κB 
inhibitor, ≥99%), CM037 (ALD1H1 inhibitor, ≥98%), and retinoic acid (≥98%) were 
purchased from Cayman Chemical Company (Ann Arbor, MI, USA). The stock solution 
of these compounds were prepared in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. 
Louis, MO, USA), and further diluted into McCoy’s 5A cell culture medium to prepare 
inhibitor solutions. Based on previous studies, CSCs were treated by CAY10566 (1 µM), 
DMAPT (5 µM), CM037 (4.6 µM), or retinoic acid (1 µM) for 7 days prior to SCMS 
measurement.[28, 29] 
2.2.3 CSC sorting 
          To purify CSCs for our SCMS experiments, we utilized florescence-activated cell 
sorting (FACS) (BD FACS Jazz flow cytometer, BD Biosciences, San Jose, CA, USA) 
under sterile conditions for cell isolation. Briefly, CSC spheroids formed during culture 
were dissociated using TrypLE reagents (Life Technologies, Grand Island, NY, USA), 
and then resuspended in the solution containing 0.5% bovine serum albumin BSA 
(Sigma-Aldrich, St. Louis, USA) and antibodies on ice. According to previous 
studies[18], CD133+/CD24+ population is recognized as CSCs, whereas CD133−/CD24− 
cells (HCT-116 cells) are regarded as NSCCs. In our experiments, antibodies of CD133 
conjugated with phycoerythrin (PE) and CD24 conjugated with allophycocyanin (APC) 
(Biolegend, San Diego, CA, USA) were added into cell suspension. CD133 and CD24 
double-positive cells (CD133+/CD24+) were gated using control cells that are incubated 
with IgG1 isotype controls (APC- and PE-conjugated antibodies, Biolegend, San Diego, 
CA, USA).  
2.2.4 Fabrication of the Single-probe 
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          The fabrication details of the Single-probe have been described in previous 
studies.[21] Briefly, there are three components in a Single-probe (Figure 2.1A): a needle 
pulled from dual-bore quartz tubing (outer diameter (OD): 500 µm; inner diameter (ID): 
127 µm, Friedrich & Dimmock, Inc., Millville, NJ, USA) using a laser pipet puller (P-
2000 micropipette puller, Sutter Instrument, Novato, CA, USA), a fused silica capillary 
(OD: 105 µm; ID: 40 µm, Polymicro Technologies, Phoenix, AZ, USA), and a nano-ESI 
emitter produced using the same type of fused silica capillary. A Single-probe is 
fabricated by embedding a laser-pulled dual-bore quartz needle with a fused silica 
capillary and a nano-ESI emitter.   
2.2.5 The Single-probe SCMS Set-up 
          CSCs and NSCCs were attached onto the laminin-coated glass slides through over-
night culture (Figure 2.1C), and the slides were placed on a motorized XYZ−translation 
stage system (Figure 2.1D), which was controlled by a LabView software package.[30] A 
syringe (250 µl; Hamilton Co., Reno, NV, USA) was used to continuously provide the 
sampling solvent (acetonitrile; Sigma-Aldrich St. Louis, MO, USA), and a stable liquid 
junction was formed at the Single-probe tip to extract cellular contents during the 
experiment. Using a microscope as a guide, a cell of interest was selected by controlling 
the stage system, and the selected cell was penetrated by lifting the Z-stage (Figure 2.1B). 
Cellular components were extracted by sampling solvent at the Single-probe tip, 
withdrawn towards the nano-ESI emitter through a self-aspiration process, and ionized 
for analysis using a Thermo LTQ Orbitrap XL mass spectrometer (Thermo Scientific, 
Waltham, MA, USA) (Figure 2.1D). MS scans were acquired for individual cells, 
whereas MS2 experiments were conducted for ions of interest. MS analysis parameters 
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are listed as follows: mass resolution 60,000, ionization voltage +4.5 kV (positive ion 
mode) or -4 kV (negative ion mode), 1 microscan, 100 ms max injection time, and AGC 
(automatic gain control) on. 
 
 
Figure 2.1   The Single-probe SCMS experimental set-up for the analysis of individual 
CSCs and NSCCs. (A) Photograph of a Single-probe device; (B) Zoomed-in photograph 
of the Single-probe tip probing a single cancer cell; (C) Workflow of CSC sample 
preparation; (D) The schematic diagram of the Single-probe SCMS set-up for the analysis 
of live single cells. 
 
2.2.6 Data analysis 
          We performed the pretreatment of SCMS data prior to statistical analysis. We 
exported MS data (m/z values with their relative intensities) as tab-delimited data files 
using Thermo Xcalibur Qual Browser (Thermo Scientific, Waltham, MA, USA). Only 
relatively abundant peaks (intensity > 103) were exported, whereas background signals, 
such as peaks from solvent and cell culture medium, were subtracted from MS data.[31] 
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To minimize the influence induced by fluctuations of ion signals during experiments, we 
normalized ion intensities to the total ion current (TIC). We used Geena 2 online software 
tool (http://bioinformatics.hsanmartino.it/geena2/) to preform peak alignment. The 
pretreated data were subjected to Levene’s test to assess the equality of variance of data, 
and Student’s t-test (for data with equal variance) or Welch’s t-test (for data with unequal 
variance) was then applied to obtain ions with significantly different abundance between 
two groups (p < 0.05). Metaboanalyst 4.0 (http://www.metaboanalyst.ca/) was used to 
conduct Partial Least Squares Discriminant Analysis (PLS-DA) to illustrate the overall 
differences of metabolomics profiles between CSCs and NSCCs. Finally we use online 
database METLIN (https://metlin.scripps.edu/metabo_batch.php) and human metabolome 
database (HMDB; http://www.hmdb.ca) to tentatively label all ions based on their 
accurate m/z values, whereas more confident identification of ions of interest was 
proposed based on tandem MS measurements. It is worth noting that, due to the lack of 
separation of cellular contents in the real-time SCMS measurement, we cannot 
completely exclude the coexistence of isomers producing common fragment ions in 
tandem MS. 
 
2.3 Results and Discussion 
2.3.1 Metabolic profiles of CSCs and NSCCs are significantly different 
          We used florescence-activated cell sorting (FACS) to isolate CD133+/CD24+ 
population from HCT-116 CSCs [18] prior to SCMS experiments, and utilized the 
regular HCT-116 cells as NSCCs for comparison studies. For SCMS experiments, CSCs 
and NSCCs were attached onto the laminin-coated glass sides through over-night culture 
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(Figure 2.1C), and the slides were placed on a motorized XYZ−translation stage system 
(Figure 2.1D). Using a microscope as a guide, a cell of interest was selected by 
controlling the stage system. The selected cell was penetrated by the Single-probe (tip 
size < 10 µm) for sampling of cellular contents followed by real-time MS analysis 
(Figures 2.1A and 2.1B). To obtain a broader coverage of cellular metabolites, we 
measured 60 and 40 cells from each group in the positive and negative ion modes, 
respectively. Our experimental results indicate that the positive ion mode is suitable for 
MS detection of the majority of cellular metabolites (e.g., lipids), whereas the negative 
ion mode is desired for certain organic acids (e.g., TCA cycle metabolites and fatty acids). 
Mass spectrum patterns obtained from CSCs and NSCCs are distinct, and PLS-DA 
results confirmed that their overall metabolomic features are significantly different as 
shown in Figure 2.2 (p = 0.0015 from the permutation test). 
 
Figure 2.2    Results from Partial Least Squares Discriminant Analysis (PLS-DA) of 
SCMS data illustrate the overall difference of metabolites between CSCs and NSCC. 
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2.3.2 CSCs have higher abundances of metabolites of TCA cycle than NSCCs 
          We further investigated the specific metabolites that are different between CSCs 
and NSCCs. TCA cycle, a step in the aerobic oxidative respiration, plays a critical role in 
the energetic metabolism in normal mammalian cells (Figure 2.3A). We found that 
multiple metabolites of the TCA cycle, including malic acid, citric acid, succinic acid, 
and pyruvate, have significantly higher abundances in CSCs than NSCCs  (Figures 2.3B). 
However, other relevant metabolites, including fumaric acid, α-ketoglutarate, and 
oxoglutaric acid, are present with comparable abundances (Figure 2.3B). All these 
metabolites of the TCA cycle were identified by MS2 experiments at the single cell level. 
          Our results demonstrate that the activities of TCA cycle are different between 
colonic CSCs and NSCCs at the single cell level. According to previous studies, cancer 
cells have a distinct energy metabolism pathway compared to normal cells.[32] Aerobic 
glycolysis is the major energetic source for most of cancer cells even under sufficient 
oxygen environment (known as “the Warburg effect”), while normal cells rely on the 
mitochondrial oxidative phosphorylation (OXPHOS) to provide most energy.[33] The 
TCA cycle, a cellular process supplying the material to OXPHOS,[34] is downregulated 
in cancer cells. Studies based on bulk analysis (LC-MS) found that intermediates of the 
TCA cycle are decreased in human ovarian cancer and cervical cancer cells[35], whereas 
ovarian and cervical squamous CSCs obtain energy through OXPHOS by activating the 
TCA cycle.[36] In fact, CSCs can utilize different energy metabolism pathways based on 
their phenotypes,[36, 37] and they maintain the homeostasis by switching their energy 
metabolism pathways between OXPHOS and glycolysis.[38] In the present study, we 
identified multiple intermediates of the TCA cycle (including pyruvate, citric acid, malic 
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acid, and succinic acid), and demonstrated they are significantly upregulated in CSCs 
than NSCCs. Our results may suggest that the dominant energy metabolism pathways are 
different for HCT-116 CSCs and NSCCs under our experimental conditions (Figures 
2.3A and 3B).  
 
 
Figure 2.3    Comparison of abundances of metabolites in TCA cycle between CSCs and 
NSCCs (negative ion mode, n = 40 in each group). (A) TCA cycle pathway and the 
associated key metabolites. (B) Metabolites present at significantly higher levels in CSCs 
than in NSCCs are labeled. All metabolites were identified from MS2 and MS2 
experiments at single cell level. (From t-test: *p < 0.05; **p < 0.001) 
 
2.3.3 CSCs have higher levels of unsaturated lipids than NSCCs 
          In addition to the detection of small metabolites such as species involved in the 
TCA cycle, we observed a large number of lipids in both CSCs and NSCCs. Our 
experimental results indicate the levels of 13 unsaturated lipids are significantly higher in 
CSCs compared to NSCCs (in positive ion mode, Figure 2.4A). All of these lipids were 
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confirmed through MS2 analysis from single cells. As the building blocks of lipids, fatty 
acids were also detected in both CSCs and NSCCs in the negative ion mode. The ratios of 
monounsaturated fatty acids (MUFAs) to saturated fatty acids (SFAs), e.g., palmitic 
acid/palmitoleic acid (C16:0/C16:1) and stearic acid/oleic acid (C18:0/C18:1), are 
significantly higher in CSCs compared to NSCCs (Figures 2.4B and 2.4C).  
          We observed drastically different levels of unsaturated lipids and fatty acids 
between CSCs and NSCCs through SCMS analysis (Figures 2.4A and 2.4B). Relatively 
higher abundances of unsaturated lipids in CSCs are likely related to the formation of 
lipid droplets.[39] Previous studies found that in CSCs de novo fatty acid synthesis 
pathway is upregulated, and lipids storage compartment, lipid droplets (LDs), are 
accumulated.[40] Increasing amount of evidence indicates that lipid molecules and lipid 
droplets are essential for the stemness and tumorigenicity of CSCs.[40] For example, a 
recent study reported a higher degree of LDs accumulation in different patient-derived 
colon CSCs than normal cancer cells using hyperspectral-stimulated Raman spectroscopy 
and LC/MS, and relatively more abundant LDs are positively correlated with the 
tumorigenic potential of CSCs.[41] 
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Figure 2.4    Saturation levels of lipids and fatty acids in CSCs and NSCCs. All species 
were identified from MS2 experiments at single cell level. (A) CSCs contain relatively 
higher abundances of unsaturated lipids compared to NSCCs (positive ion mode, n = 60 
in each group). (B) Relative abundances of fatty acids (C16:0, C16:1, C18:0, and C18:1) 
detected in CSCs and NSCCs (negative ion mode, n = 40 in each group). (C) Ratios of 
unsaturated fatty acid (UFA) to saturated fatty acid (SFA) in CSCs and NSCCs. (From t-
test: *p < 0.05; **p < 0.01; ***p < 0.001). 
 
          Interestingly, correlations between metabolites of TCA cycle and unsaturated lipids 
were also discovered in CSCs. We conducted correlation analysis of species measured 
from same cells, and found positive correlations (correlation coefficinet > 0.6, p < 0.01) 
between pyruvate and each of these fatty acids:  C16:0, C16:1, C18:0, and C18:1. 
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Because pyruvate can be converted into acetyl-CoA, which is directly involved in the 
sythesis of fatty acids, by pyruvate dehydrogenase,[42] higher levels of pyruvate likely 
lead to more production of fatty acids, including unsaturated fatty acids. 
          In addition to those species reported in previous LC-MS studies (i.e., palmitic 
(C16:0), palmitoleic (C16:1), stearic (C18:0), oleic (C18:1), linoleic (C18:2), arachidonic 
(C20:4), and docosahexaenoic acid (C22:6)), we discovered additional unsaturated lipids 
with drastically different abundances between CSCs and NSCCs. For example, 
phosphatidylcholines (PC(16:0/22:5), PC(32:3), PC(14:0/18:1), PC(34:4), PC(34:5), 
PC(34:1), PC(15:0/20:3), PC(16:1/18:2), PC(18:1/18:2), PC(14:1/18:3)), diglyceride 
(DG(38:6)), and triglycerides (TG(16:1/18:1/18:4), TG(14:1/16:1/20:4)) are present at 
significantly higher abundances in CSCs than NSCCs (Figures 2.4A and 2.4B). Higher 
levels of unsaturated lipids and fatty acids are mainly produced by stearoyl-CoA 
desaturase-1 (SCD1) enzyme, and they are directly associated with the stemness of 
CSCs.[28]  
2.3.4 Inhibition of SCD1, NF-κB, and ALDH1A1 reduces the stemness of CSCs 
          Previous studies indicate that SCD1, nuclear factor κB (NF-κB), and aldehyde 
dehydrogenases (ALDH1A1) play critical roles in maintaining the abundances of 
unsaturated lipids in CSCs.[28] We conducted SCMS experiments to investigate their 
functions regulating the saturation level of lipids and fatty acids, and the consequential 
influence on the stemness of CSCs. Overall, PLS-DA indicates that metabolomic profiles 
of CSCs were significantly altered (p < 0.05 from permutatoin test) by these inhibitors. 
Because inhibitors used in our experiments can induce cell apoptosis[43-45], it is unclear 
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if changes of cell metabolites are related to cell apoptosis, although cells are still alive 
prior to the SCMS measurements. 
 
Figure 2.5    Ratios of monounsaturated fatty acid (MUFA) to its saturated fatty acid 
(SFA) in CSCs under different treatment conditions (negative ion mode, n = 40 in each 
group). (From t-test: *p < 0.05; ***p < 0.001). 
 
          Stearoyl-CoA desaturase-1 (SCD1) is one of the major lipid desaturases catalyzing 
the conversion of SFAs to MUFAs in mammalian cells, and the major products of SCD1 
are palmitoleic (C16:1) and oleic acid (C18:1).[46] A recent study shows that SCD1 is a 
key factor mediating the expression of desaturated lipids and fatty acids in ovarian cancer 
cells.[28] To determine whether SCD1 plays a role in regulating the expression of 
unsaturation lipids and fatty acids in colorectal CSCs, we treated CSCs with CAY10566, 
a small molecule inhibitor of SCD1, to suppress the activity of SCD1.[47] As shown in 
Figures 2.5 and 2.6A, the ratios of MUFAs to SFAs (C16:1/C16:0 and C18:1/C18:0) and 
the abundances of numerous unsaturated lipids  are drastically decreased in CSCs treated 
with CAY10566, indicating the expression of unsaturated lipids and fatty acids can be 
regulated by SCD1. Interestingly, PC(16:0/22:5) exhibits an opposite trend: its abundance 
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is increased after CAY10566 treatment. A reasonable explanation follows: inhibiting 
SCD1 can reduce the synthesis of C16:1 from C16:0, result in  the accumulation of C16:0, 
and further increase the synthesis of lipids using C16:0, such as PC(16:0/22:5), through 
competative pathways. Moreover, we found that CSCs treated with CAY10566 possess 
significantly lower tendencies to form spheroids during cell culture. Because forming 
spheroids in serum-free medium is an important feature of CSCs[48], our results suggest 
CAY10566 impacts the formation of speroids and reduces the stemness of CSCs.[28] We 
conclude that levels of unsaturated lipids and fatty acids can be regulated by SCD1, and 
their abundances are important for the maintenance of the stemness of CSCs, which is 
consistent with the previous studies.[28] 
          In addition to directly suppressing the activity of SCD-1, we investigated the 
influence of nuclear factor κB (NF-κB) and aldehyde dehydrogenases (ALDH1A1), 
which are crucial for regulating SCD1 activities and maintaining the stemness of ovarian 
CSCs[28], on metabolites of CSCs. NF-κB is a protein complex that is essential for DNA 
transcription, cytokine production, and cell survival.[49, 50] NF-kB is extensively tied to 
cancer biology, and tightly related to cancer stem cell.[51, 52] Particularly, NF-κB 
signaling is highly sensitive to the inhibition of desaturase, which is related to the 
stemness of CSCs.[28] ALDH1A1 is one of the major enzymes producing retinoic acid 
(RA), which is also a well-known biomarker of colon CSCs.[53] To investigate whether 
NF-κB and ALDH1A1 are associated with lipid saturation and the stemness of CSCs, we 
treated CSCs with inhibitors of NF-κB and 
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Figure 2.6    The investigation of roles of SCD1, NF-κB, and ALDH1A1 in regulating 
the saturation levels of lipids and fatty acids in CSCs (positive ion mode, n = 60 in each 
group). Expression of unsaturated lipids is decreased by inhibitors of (A) SCD1 
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(CAY10566), (B) NF-κB (DMART), and (C) ALDH1A1 (CM037). (D) Retinoic acid 
(RA) rescues the inhibition by CM037 and results in increased levels of unsaturated 
lipids. (From t-test: *p < 0.05; **p < 0.01; ***p < 0.001). 
 
ALDH1A1 (i.e., dimethylaminoparthenolide (DMAPT) and CM037[29, 54], 
respectively). Experimental results show that these two inhibitors significantly 
suppressed the expression of unsaturated lipids and fatty acids (Figures 2.5, 2.6B, and 
2.6C), and drastically hindered the formation of CSC spheroids, i.e., reduced stemness of 
CSCs. We conclude that the NF-κB and ALDH1A1 affect the growth of CSCs.  
          Because RA is an important product of ALDH1A1[55], inhibiting the activity of 
ALDH1A1 will apparently lead to a reduced production of RA. This consequence is 
likely related to the altered properties of CSCs such as the reduced stemness. It is 
reasonable to hypothesize that increasing RA supply during the cell culture will likely 
alleviate the inhibition by CM037. We then treated CM037-inhibited cells with RA, and 
observed that the levels of unsaturated fatty acids and lipids were significantly restored in 
CM037-inhibited CSCs (Figures 2.5 and 2.6D). Taken together, we demonstrate SCD1, 
NF-κB, and ALDH1A1 are important regulating factors in CSCs, and they are 
responsible for the expression of higher levels of unsaturated lipids and fatty acids to 
maintain the stemness of CSCs. 
2.2.5 Activities of SCD1, NF-κB, and ALDH1A1 regulate the stemness of CSCs.  
          As summarized in Figure 2.7, we demonstrate that SCD1, NF-κB, and ALDH1A1 
participate in the regulation of the saturation levels of lipids and fatty acids, and further 
affect the stemness of CSCs. First, we found SCD1 inhibitor (CAY10566) can reduce the 
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levels of unsaturated lipids in CSCs and inhibit the formation of CSC spheroids (Figures 
2.6A), indicating that SCD1 activity is important for the stemness and tumorigenicity of 
CSCs. Second, we investigated the influence of inhibiting ALDH1A1, which is a known 
biomarker of CSCs.[56] ALDH1A1 converts retinaldehyde to RA, which functions as a 
ligand of transcription factor, i.e., retinoic acid receptor (RAR). RA regulates the 
activation of numerous nuclear transcription factors, and plays a central role in regulating 
lipid metabolism.[57] Treatment using ALDH1A1 inhibitor (CM037) significantly 
decreased levels of unsaturated lipids and suppressed spheroid forming of CSCs (Figures 
2.6C). Our results indicate that ALDH1A1 is a mediating factor of the stemness and 
tumorigenicity of CSCs, which is consistent with a previous study of ovarian CSCs.[28] 
Last, we proved that the function of NF-κB is cruicial for the maintenance of the 
stemness of CSCs. NF-κB signaling pathway is responsible for maintaining the stemness 
of CSCs[58], and it is a crucial regulator of inflammation and immune responses as well 
as multiple cancer-associated processes such as proliferation, apoptosis, angiogenesis, 
and metastasis.[59] The hyper activation of NF-κB signaling in CSCs provides a proper 
niche for the survival and expansion of CSCs, and contribute to their capabilities of 
invasion, metastatic, and self-renewal.[58, 60, 61] In this study, we found that, similar to 
the treatment effects of using inhibitors of SCD1 and ALD1H1, inhibiting the activity of 
NF-κB using DMAPT changed the metabolomic profiles, as well as decreased the level 
of unsaturated lipid and the spheroid formation of colon CSCs (Figures 2.6B), indicating 




Figure 2.7    Potential mechanisms showing the regulation of unsaturated lipids and fatty 
acids by SCD1, NF-κB, and ALDH1A1, and their relationship to the stemness of CSCs. 
 
2.4 Conclusions 
          In this study we successfully applied the SCMS technique to detecting a number of 
key metabolic features of colon CSCs, including higher levels of metabolites in the TCA 
cycle and unsaturated fatty acids and lipids. The high abundances of unsaturated lipids 
and fatty acids are the metabolic features of CSCs. SCD1 is a key factor mediating the 
expression of unsaturated fatty acids and lipids such as palmitoleic and oleic acid. 
Inhibiting the activity of SCD1 could significantly suppress the expression of unsaturated 
fatty acids and lipids. In addition, NF-κB and ALDH1A1 play critical roles in 
maintaining stemness of CSCs, and also regulate the expression of unsaturated lipids. 
Together, we demonstrate that SCD1, NF-κB, and ALDH1A1 regulate the metabolism of 
unsaturated lipids and fatty acids, which are associated with the stemness of CSCs, at 
single cell level. Our current study indicates that the Single-probe SCMS technique can 
be applied to analyze live single CSCs, and our findings can promote the understanding 
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of the biological characters of CSCs. Moreover, because metabolic features and 
regulatory factors detected here are deeply associated with the stemness and 
tumorigenicity of colon CSCs, they can be potentially used as the functional biomarkers 
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Chapter 3.     Metabolomic Fingerprints of Individual Algae Cells using 
the Single-Probe Mass Spectrometry Technique 
 
3.1 Introduction  
Globally, marine phytoplankton contribute ca. 45 petagrams carbon per annum to 
net primary production (NPP) [1]. Phytoplankton are thus important drivers of several 
global biogeochemical cycles, notably of elements that are components of cellular 
biomass, including carbon (C), nitrogen (N), phosphorus (P), silicate (Si), and others. The 
abundance of phytoplankton in marine systems is shaped by the availability of nutrients 
as well as physical oceanic processes. Typically, phytoplankton biomass can be broadly 
approximated from environmental variables, such as nutrient concentrations, sea surface 
temperature, and solar irradiance [1, 2]. However, at a more granular level, such as the 
cellular response of individual phytoplankton to dynamic oceanographic conditions, 
requisite adaptations are often not well understood. In particular, whether phytoplankton 
are nutrient limited in the environment has long attracted the attention of oceanographers 
who are trying to understand the controls on NPP, given the large impact that limitation 
may have on the structure of marine ecosystems. 
Historically, both N and P have been understood to, at times, limit productivity in 
marine systems [3], but other nutrient, such as iron [4, 5], also appear to play an 
important role.  Additionally, phytoplankton can be co-limited by more than one nutrient 
due to their limited absolute abundance (i.e., kinetic limitations), or the acquisition of one 
nutrient may be dependent on the concentration of another [6].  Understanding requisite 
limitations in natural systems is unfortunately not a straightforward matter, given the 
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restricted methodological options available to researchers.  For example, nutrient 
limitation is frequently invoked via nutrient ratios (Liebig’s law of the minimum), yet this 
ignores that turnover rates can be high in the face of low, but non-limiting ambient 
concentrations [7, 8].  Similarly, bottle incubations (spiking nutrients) are used to infer 
nutrient limitation via measurements of cellular activity (e.g., carbon fixation), biomass 
(e.g., chl a), or photosynthetic capacity (Fv/Fm), but interpretation of requisite data can be 
challenging, given that measurements are made on bulk communities in which individual 
phytoplankton species may exhibit differential behavior.  Changes in elemental uptake 
ratios (C: P or C: N) have been used to infer nutrient limitation [7, 9], but such analyses 
suffer from drawbacks similar to those of bottle incubations, in that measurements are 
conducted on bulk communities. 
 An alternate avenue has been the development of specific molecular probes for 
the expression of marker genes. This approach draws on a long tradition of studies that 
aim to develop molecular targets for specific microbial nutrient cycling activities in the 
environment [10-12](and many more).  For example, the expression of the global 
nitrogen regulator NtcA in marine cyanobacteria has been used to assess the nutritional 
status of natural populations of Synechococcus [13].  Similarly, the expression of the nifH 
gene is widely distributed in marine systems [14], indicator of cellular alleviation of N 
limitation in some microbial populations. However, while this approach is powerful, it 
typically requires a fairly good understanding of the underlying molecular mechanisms 
and genetic diversity of related genes to allow for the derivation of probes or primers.  
Other studies have applied less targeted, transcriptomic approaches to detect nutrient 
limitation in marine phytoplankton [15-17], but analogous studies are more difficult in 
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diverse natural assemblages for which genetic information is not necessarily available.   
Given this, our understanding of the degree and severity of nutrient limitation in the 
marine environment, especially at the induvial species and cellular level, remains poorly 
constrained. 
            Recently, several approaches have been developed to perform the single cell 
analysis. These include fluorescence, capillary electrophoresis, and mass spectrometry 
(MS)[18-22]. Here we report the application of a novel technology that allows for the 
analysis of the metabolome of single phytoplankton cells to assess their physiological 
status. The approach utilizes the ‘Single-probe’, a micro-scale sampling and ionization 
device, that is coupled to an XYZ-stage to directly insert into single phytoplankton cells 
to extract cellular metabolites for real-time MS analysis [23, 24]. Our aims were threefold.  
First, we intended to establish a proof of concept, i.e. demonstrate that metabolome data 
could be generated for single marine phytoplankton cells.  Second, we aimed to 
demonstrate that physiological changes at the cellular level could be detected via analysis 
cellular metabolites sampled.  Lastly, we aimed to demonstrate that single cell 
metabolomics can be utilized to assess whether cells are experiencing different 
illumination levels and nutrient limitation.  
 
3.2 Materials and methods 
3.2.1 Cultures 
Non-axenic Scrippsiella trochoidea CCMP 3099 was originally obtained from the 
National Center for Marine Algae and Microbiota (Provasoil-Guillard NCMA, Boothbay 
Harbor, ME). For maintenance, cultures were grown in L1 seawater media [25-27].  
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Media was prepared from natural seawater collected near Key West (salinity of 33), 
which was aged for at least six month in the dark and autoclaved.  Maintenance and 
experimental cultures were grown in a light/dark incubator at 23-24 °C and 30-40 µmol 
quanta·m-2s-1 light under a 12-h light:12-h dark cycle.  
3.2.2 Experimental Culture Setup. For the light/dark comparisons, cultures were grown 
under replete conditions in full L1 media containing 880 µM NaNO3 and 36 µM 
NaH2PO4 (N/P ratio 24:1). Experimental cultures were started as a 1:10 inoculum from 
exponentially growing cultures into 1L of media in 2.5 L Pyrex Fernbach flasks without 
shaking and monitored daily via cell counts and chlorophyll measurements. Cell counts 
were conducted by addition of 1% Lugol’s iodine and direct counting of cells in 96-well 
microtiter plates using a dissection microscope.  Dilutions were made as necessary and at 
least 10 wells containing 100 µL diluted culture were counted to average cell counts. 
Chlorophyll a was measured via fluorometry [28] by filtering 5 mL of culture in triplicate 
onto GF/F filters, over-night extraction with methanol, and quantification using a Turner 
Trilogy Laboratory Fluorometer. Cultures were grown into late-log phase (data not 
shown) and then sampled three hours before and three hours after the light was turned on.  
Cultures were sub-sampled for MS analysis, making sure to keep ‘dark’ sample exposure 
to light to a minimum by wrapping sampling tubes in aluminum foil. 
N-deplete cultures were generated by first growing cells on L1 media with an N:P 
ratio of 2.4:1 (88 mM nitrate: 36mM phosphate) analogous what has been previously 
described [15]. This lower ratio stoichiometrically limited cultures in nitrogen and at least 
three transfers were performed to ensure no carryover from higher nutrient full L1 
medium.  Cultures were monitored daily via cell counts (see above), chlorophyll a 
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quantification (see above), and quantification of nitrate/nitrite via a Vanadium reduction 
method [29]. Parallel cultures were set up in which one culture was allowed to run out of 
nitrogenous nutrients (N-deplete), while the culture (control) was fed additional nitrate 
every second day to bring total nitrate/nitrite concentrations back to starting levels.  Once 
nitrate/nitrite levels dropped below the limit of detection (~1-2 µM) in the N-deplete 
culture, cultures were grown for an additional 24 hours before sampling to ensure that N-
depletion was complete.  Both the N-deplete and replete cultures were then sampled for 
MS analysis of single cells.  
3.2.3 MS   
Individual cells of S. trochoidea were analyzed via the ‘Single-probe’ MS techniques. 
Detailed fabrication protocols of the Single-probe have been previously described [23, 30, 
31]. Briefly, a Single-probe (Figure 3.1A) has three components: a dual-bore quartz 
tubing (outer diameter (OD) 500 µm; inner diameter (ID) 127 µm, Friedrich & Dimmock, 
Inc., Millville, NJ, USA) pulled using a laser pipette puller (P-2000 micropipette puller, 
Sutter Instrument, Novato, CA, USA), a fused silica capillary (OD 105 µm; ID 40 µm, 
Polymicro Technologies, Phoenix, AZ, USA), and a nano-ESI emitter made from the 
same type of fused silica capillary. A Single-probe is fabricated by embedding a fused 
silica capillary and a nano-ESI emitter into both of the channels of the laser-pulled dual-
bore quartz needle.  
For the analysis, cells were deposited onto 0.2 µm polycarbonate membranes by 
gentle filtration, and the cells were rinsed with phosphate buffered saline (PBS; 137 mM 
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4; pH of 7.4) to remove culture 
medium. Filters were then placed on a home-built XYZ−translation stage system and 
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spatial motion was controlled by a custom designed LabView software package [32]. The 
Single-probe tip (<10 µm) was then precisely insert into single S. trochoidea cells 
(typically ~20-30 µm cellular diameter) using a microscope as a guide (Figure 3.1B). 
During the experiment, a syringe (250 µl; Hamilton Co., Reno, NV, USA) was used to 
continuously provide the sampling solvent (acetonitrile; Sigma-Aldrich St. Louis, MO, 
USA), and a liquid junction formed at the Single-probe tip to perform highly efficient 
extraction of cellular contents. The analytes were withdrawn by capillary action towards 
the nano-ESI emitter, and ionized for analysis using a Thermo LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, Waltham, MA, USA)(Figure 3.1C). Mass analyze 
parameters were as follows: mass resolution 60,000, +4 kV ionization voltage at positive 
ion mode (0.05-0.07 µA of ion current), 1 microscan, 100 ms max injection time, and 
automatic gain control on. 
3.2.4 Data Analysis 
 The Thermo Xcalibur Qual Browser (Thermo Scientific, Waltham, MA, USA) 
was used to export MS data (m/z values with relative intensities) as tab-delimited data 
files. As a conservative approach, only relatively abundant peaks with ion intensities > 
103 were exported.  This approach excluded 6% of low signal peaks as background while 
retaining 94 % of total signal intensity. The relative ion intensities were normalized to the 
total ion current to minimize the influence induced by fluctuations of ion signals during 
experiments. The Geena 2 online software tool 
(http://bioinformatics.hsanmartino.it/geena2/) was then used for peak alignment [33], and 
the aligned m/z values were then used for comparisons. Parameters used in Geena 2 
include analysis range (from 100m/z to 1500 m/z), maximum number of isotopic replicas 
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(5), maximum delta between isotopic peaks (0.05 Da), and maximum delta for aligning 
replicates (0.01 Da). Metaboanalyst 3.0 (http://www.metaboanalyst.ca/) was used to 
 
Figure 3.1    Experimental setup to measure single S. trochoidea cells using the “Single-
probe” MS techniques. (A) Photograph of the Single-probe device with its different 
components labeled (B) Image from microscope-linked camera used to target single S. 
trochoidea cell with the Single-probe; (C) Setup used to manipulate the Single-probe MS 
device with components labeled. 
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tentatively label all ions of interest [36, 37], to perform hierarchical clustering, and to 
generate heat maps. Lastly, Pathos (http://motif.gla.ac.uk/Pathos/) was used to attempt 
identification of significantly regulated metabolic pathways by considering all KEGG 
maps in all organisms [38].   
 
3.3 Result 
The main aims of this study were to develop a single-cell-based metabolomic 
methodology that could be applied to individual algal cells and to demonstrate that this 
technology can detect physiological responses to environmental stimuli. The described 
setup allowed us to sample individual cells by targeting them with the tip of the Single-
probe (Figure 3.1B).  Our ‘proof of concept’ experiment involved a comparison of cells 
in the context of diurnal illumination changes, which are known to induce significant 
changes in algal cellular metabolomes [39].  
 Using the Single-probe MS technique, distinct and clear differences were 
observed in the S. trochoidea metabolome under different light levels.  A total of 1,085 
and 1,103 metabolites were detected under light and dark conditions respectively.  Of 
these, 306 and 321 were differentially abundant among treatments (t-test; p< 0.05). 
Partial Least Squares Discriminant Analysis of all detected metabolites (PLS-DA) 
(Figure 3.2A and Table 3.2) revealed that metabolic features formed distinct clusters (15 
cells in each group), and this difference was highly significant (p= 5*10-4; permutation 
test in Metaboanalyst 3.0).  To investigate which metabolic pathways may have been 
significantly impacted by the difference in illumination levels, all ions with significant 
differences (p<0.05) were selected and tentatively labeled by searching their m/z values 
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in Pathos, considering all KEGG metabolites, and retaining pathways for which at least 2 
hits were observed (Table 3.1).  A criterion of two hits to an individual pathway was used, 
because the reliability of assignments for metabolites based on m/z values alone is 
limited. Most strikingly, only 12 (5%) and 16 (19%) of differentially abundant 
metabolites could be assigned to KEGG pathways for light and dark conditions 
respectively, indicating that the majority of the metabolic response to light changes in S. 
trochoidea is not captured in KEGG metabolic maps.  With respect to pathways with at 
least two hits (Table 3.1), light favors biosynthesis of molecules potentially linked to the 
production of 12-, 14- and 16-membered macrolides. In particular, several hits in the 
pathway for Avermectin were observed (Table 3.1A).  Under dark conditions, identified 
pathways included those for polyketides, porphyrin, chlorophylls, terpenoids, and 
limonene (Table 3.1B).   With respect to the four hits in porphyrin and chlorophyll 
metabolism, all were linked to the production of phycobillins.   
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Table 3.1   Pathways containing more than one metabolite with significantly different 
abundance under (Table 3.1A) illuminated conditions compared to cultures during (Table 
3.1B) dark condition.  Metabolites were analyzed using Pathos 
(http://motif.gla.ac.uk/Pathos/pathos.html) by considering all KEGG maps in all 
organisms under positive ion mode. 
 
 Given the successful proof of concept for light/dark conditions, we aimed to 
investigate whether single cell metabolomic analysis might be utilized to investigate the 
nutritional status of individual phytoplankton cells.  As shown in Figure 3.2B and Table 
3.2, PLS-DA results indicated that single cellular metabolomes of S. trochoidea under N-
limited condition were clearly different from those in nitrogen replete cells (n = 10). As 
with the light-dark treatments, N limitation induced a highly significant response (p= 
1*10-3; permutation test in Metaboanalyst 3.0). KEGG pathway analysis was attempted, 
but yielded no metabolites in the significantly upregulated pool that could be matched to 
KEGG.  Similarly, only 8 (<4.5%) metabolites from the down-regulated pool could be 
mapped with KEGG and no pathways contained more than a single hit.  Little 
information could therefore be gleaned about requisite physiological responses via 
KEGG analysis, and an alternative approach to analysis was therefore taken.  First, we 
hypothesized that N-limitation should be reflected in the C/N and N/P rations of the 
cellular metabolome, as cells might physiologically adjust to environmental conductions 
by choosing cellular metabolites with lower N content [7, 40].  Second, metabolites were 
analyzed for the putatively detected N-containing lipids (e.g. phosphoethanolamine), 
given that physiological responses are often manifest in the lipid pool.  
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Figure 3.2    Partial Least Squares Discriminant Analysis (PLS-DA) of MS data.  All 
detected metabolites were analyzed, visualizing the overall effect on the metabolome of 
single S. trochoidea cells by (A) light vs dark conditions (results are reported from 15 
replicates (n=15) in each group), and (B) N-limited vs. replete conditions (n=10 for each 
group). 
 
 (A) R2 and Q2 values for light vs dark model 
	
Measure	 1	comps	 2	comps	 3	comps	 4	comps	 5	comps	
Accuracy	 0.97619	 0.97619	 0.97619	 0.97619	 0.97619	
R2	 0.86165	 0.97386	 0.99618	 0.99883	 0.99974	
Q2	 0.72835	 0.8285	 0.84477	 0.84725	 0.84978	
	
(B) R2 and Q2 values for N-limited vs replete model 
	
Measure	 1	comps	 2	comps	 3	comps	 4	comps	 5	comps	
Accuracy	 0.9	 0.95	 0.9	 0.9	 0.9	
R2	 0.79324	 0.96464	 0.89568	 0.89955	 0.89994	
Q2	 0.59696	 0.64163	 0.63966	 0.64254	 0.64297	
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Table 3.2   PLS-DA cross-validation results. Presented are the performance measures (R2 
and Q2) for different number of components. 
 
 C: N and C: P ratios were calculated by summing the product of the number of C, 
N, P atoms in each metabolite with its relative abundance across all metabolites.  This 
analysis reveals that N-limited S. trochoidea has significantly higher C:N ratios in 
regulated metabolites as compared to replete conditions (p=4*10-6). Similarly, C:P ratios 
were affected and were significantly higher under N-limitation (p< 0.044).  Concurrently, 
the abundances of at least some cellular lipids were significantly affected. When all 
significantly regulated metabolites putatively identified as lipids are considered (Figure 
3.4), it appears that the availability of light correlates with both up- and down-regulation 
of specific lipid complements (Figure 3.4A).  Under N-limitation, however, a significant 




Figure 3.3    Elemental ratios of significantly regulated metabolites.  (A) Carbon to 
Nitrogen ratio; (B) Carbon to Phosphorus ratio. 
 
Figure 3.4    Heat maps generated from hierarchically clustering summarizing the 
cellular lipids measured from single S. trochoidea cell under different light and nutrient 
conditions. Only lipids for which abundances were significantly different among 
treatment pairs are shown. Shown are differences for (A) light vs. dark conditions and (B) 
replete vs nitrogen (N) limiting conditions.  Red indicates elevated and green indicates 
decreased signal with respect to the mean signal observed for all tested cells. PA 
(phosphatic acid), PE (phosphoethanolamine), PG (phosphatidylglycerol), PS 
(phosphatidylserine), PI (phosphatidylinositol), PC (phosphatidylcholine), MG 






Historically, the majority of oceanographic research has targeted natural 
populations of phytoplankton via bulk filtration techniques (e.g. filtration onto GF/F 
filters) to assess physiological responses to environmental factors such as light or nutrient 
limitation.  While much has been learned using bulk filtration, requisite approaches suffer 
from important limitations.  Most notably, individual populations or different species are 
not adequately resolved in this manner. It is also now well appreciated that cellular 
functions, such as gene expression, proliferation, or programmed cell death, are subject to 
significant stochasticity, leading to high cellular chemical and phenotypic diversity at the 
single cell level, potentially obscuring some important patterns [41-43]. Single-cell 
analysis is therefore an attractive methodological choice when studying rare types of cells 
(cells available are inadequate for bulk analysis) or cells in heterogenous populations, 
where cell separation or sorting are impractical. Here we present the first report of a 
single cell-based metabolomic technology that allows for the analysis of intracellular 
intermediates of individual phytoplankton cells.  The Single-probe directly collects 
cellular contents of living cells, and it does this without significant sample preparation 
steps (e.g. filtration or solvent extraction), thereby allowing for real-time and targeted 
analysis that minimizes sampling artifacts.  
We note that bulk analyses (e.g., liquid chromatography (LC)/MS, gas 
chromatography (GC)/MS), or direct-injection MS without separation) were not 
conducted in this study. It is likely that the number and the types of metabolites detected 
here differs from those that might have been observed in bulk measurements. Traditional 
LC/MS and GC/MS techniques have certainly been used in the analysis of marine algae 
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[44, 45], and their value is clear in requisite studies.  However, a direct comparison was 
not conducted, because we do not view the use of the Single-probe as a replacement for 
more traditional bulk biomass approaches.  Rather, single-cell analysis can serve as a 
complementary methods that allows exploration of inherent cell-to-cell variability in 
complex and heterogeneous systems that may not be resolved using more traditional 
approaches. 
Given the tip size of the Single-probe, which is ca. 10 µm in diameter, analysis is 
currently limited to larger phytoplankton and protists.  However, the currently applicable 
size range includes many important bloom forming algae, including toxin producing 
genera such as Karenia (20-40 µm) or Pseudonitschia (40-175 µm).   The Single-probe 
might therefore offer unique opportunities to help understand the biological forces that 
shape the success of these organisms in an ecosystem by revealing their metabolomic 
responses to changing environmental conditions or experimental treatments at the cellular 
level. We note that the expensive and bulky configuration of equipment described here 
still precludes easy field deployment, making the Single-probe MS technique most useful 
under conditions where direct access to the lab is available, or when experimental 
cultures are assayed.  Further development in the miniaturization of high-resolution mass 
spectrometer or sample preservation maybe be helpful in this regard. In addition, due to 
the limited amount of cytoplasm found in an individual cell and limitation on the 
achievable sensitivity of mass spectrometers, most single cell MS studies to date are 
primarily focused on the analysis of relatively small molecules such as metabolites and 
peptides [46]. The detection of larger molecules, such as proteins presenting as relatively 
lower abundances, at single cell level remains very challenging.  
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Despite these limitations, single-cell MS technique holds great promise for 
environmental research.  The Single-probe MS technique has been successfully used to 
study live single cancer cells [23, 47], to map biomolecules on animal tissues with high 
spatial resolutions [24, 30, 48], and to analyze the extracellular metabolites inside 
spheroids [31].  With respect to the ability to detect a large range of cellular metabolites 
from single cells (i.e. from only a few pico-litters of cytoplasm sampled from a cell with 
a diameter of approximately10 µm), the Single-probe MS setup provides excellent 
detection sensitivity. We note, however, that single cell MS measurements are not strictly 
repeatable (cellular contents are consumed in each measurement), and that it is 
impractical to evaluate reproducibility in this regard. Multiple cells must therefore be 
measured (e.g., n = 10-15 in each group in the current study) to normalized intensities for 
statistical data analysis and to minimize the influence of uncertainties such as fluctuation 
of ion signals, minor changes of experimental tuning conditions, instrument noise, and 
variances associated with the matrix effect. 
Here, were extend these advances by demonstrating that the physiological status 
of phytoplankton with respect to light and nutrients can be assessed. The availability of 
light was correlated with a highly significant response in the metabolite profile of S. 
trochoidea cells (Figure 3.2).  As might be expected, metabolites related to porphyrin and 
chlorophyll pathways stood out. In particular, the detected metabolites are related to 
phytochrome metabolism, which is consistent with the notion that phytochromes are 
signal-transducing photoreceptors [49]. Beyond phototaxis and a handful of secondary 
metabolite intermediates, however, few metabolites could be assigned to KEGG 
pathways.  This, perhaps, speaks to our limited understanding of metabolism in 
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Dinoflagellate algae.  Transcriptomic analysis of S. trochoidea (same strain used here) 
indicated that this species makes perhaps in excess of 105 transcripts, the majority of 
which could not be annotated [16].   
 Cellular lipids have been used to parse physiological responses of living cells 
under different illumination conditions [50, 51].  For example, under dark conditions, 
mRNA for some genes involved in lipid biosynthesis have been observed to be elevated 
in Chlorella [51]. Differential responses of lipid abundance have also been observed in 
the marine dinoflagellate Prorocentrum minium under dark vs. light conditions [52], and 
light-induced significant changes in the fatty acid profiles have been reported for 
freshwater diatom, chrysophyte, cryptophyte, and zygnematophyte algae [50]. 
Differences in requisite light-dependent cellular lipid profiles are thought to be related to 
alterations of energy storage and the compositions of chloroplast membranes [53-55]. 
Consistently, our experiments indicated both up- and down-regulation of lipids in 
response to light in S. trochoidea.  The pattern of changes in lipid composition in 
response to N-limitation was, however, quite different from that observed under light 
limitation.  Most notably, all differentially regulated lipids were more abundant under the 
nutrient limiting conditions.  This is potentially the result of limitation induced 
imbalances in cellular elemental composition.  Under N-limitation almost all parts of 
central metabolism are impacted (and potentially slowed due to limiting resources), yet 
lipids, for the most part, do not contain N atoms and their biosynthesis might thereby 
proceed so long photosynthesis can proceed.  Whether lipid accumulation in Scrippsiella 
is adaptive, however, by possibly allowing energy storage to gain advatages when 
nutrients are more readily available, or is simply a consequence of the onset of 
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senescence remains to be investigated. Changes in the C:N and C:P ratios do appear to be 
reflected in the metabolome overall (Figure 3.3).  This observation is consistent with the 
notion that elemental ratios have considerable plasticity based on nutrient availability 
[40].  Previous studies have suggested that nutrient deficiency can cause the 
accumulation of lipids, such as triglyceride [56-58], and that phytoplankton funnel excess 
NADPH to the biosynthesis of triglyceride and fatty acids to regenerate NADP+ [56, 59, 
60]. Correspondingly, we observed that a number of triglycerides significantly increased 
in the N-limited group (Figure 3B). We also note that C:N and C:P ratios reported here 
deviate from Redfield’s expectations (C:N:P ~ 106:16:9) (Figure 3.3A). However, these 
observations are consistent with our approach.  The elemental Redfield ratios are based 
on all cellular components, yet data analyzed here only covers a subset of all cellular 
constituents.  For example, the Single-probe MS techniques cannot currently measure 
large biomolecules such as proteins and nucleic acids which are N-rich.  The absence of 
nucleic acids in calculations likely leads to high C:P ratio estimates [40, 61, 62]. Values 
reported here are therefore not inconsistent with generally expected elemental ratios for 
phytoplankton biomass. 
            In summary, we report the development of a methodology for single-cell 
metabolomics of small protists such as marine dinoflagellate algae.  Using the Single-
probe MS technology we can efficiently monitor the cellular physiological responses of 
phytoplankton under different illumination and nutrient conditions. This offers the 
opportunity for real-time analysis of natural populations and has the potential ability to 
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Chapter 4.      Cancer Cells Escape Irinotecan Chemotherapy by 
Entering Stemness Associated with the SCD1 
 
4.1 Introduction 
           Cancer is the one of the devastating disease in the world[1], and chemotherapy is 
one of the major treatment options for cancer [2], which can be used to treat cancers with 
different stages and also be used as an adjuvant therapy for advanced after surgery.[3] 
Drug resistance can largely reduce the therapeutic efficiency and finally cause the 
chemotherapy failure.[4] Therefore, it is important to understand the drug resistant 
mechanisms to promote the development of more efficient therapy for cancer. 
           Previous studies have revealed a number of general drug resistant mechanisms, 
including enhanced drug efflux, increased drug inactivation, promoted DNA damage 
repair, and suppressed apoptosis pathway.[4, 5] Accumulating evidence indicates that the 
development of drug resistance is associated with alteration of metabolic profiles. For 
example, previous studies indicated that amino acids and nucleobases (i.e., pyrimidines 
and purines) are enriched by irinotecan treatment.[6-8] However, the specific metabolic 
different have not been fully understood, and the role of metabolic changes in the 
development of drug resistance in cancer cells is largely unknown. Additionally, studies 
of cells with the acquired resistance in clinic were generally based on long-term 
chemotherapy [9]. For example, in many studies cancer cells were treated with anticancer 
drug for more than a year to develop the drug-resistant cell models, which possess over 
100-time higher drug resistance than their parental cells. However, a very few studies 
have been focused on the metabolic features and biological changes of cancer cells at the 
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early stage of drug resistance development. Understanding the metabolic changes and 
gene regulation involved in the beginning of drug resistance development can reveal the 
relevant mechanisms and eventually benefit the disease management. 
           In addition to the metabolic changes, recent studies reported that chemotherapy 
treatment leads to the induced cancer stem cells (iCSCs), which are stem-like cells with 
self-renew and spheroid formation characteristics [10]. The iCSCs can be isolated from 
various types of tumors, and they possess high levels of resistant to many anticancer 
drugs such as oxaliplatin and 5-fluorouracil.[11, 12] Importantly, iCSCs also promote 
tumor recurrence and metastasis.[13, 14] However, the specific mechanism of drug 
induced stemness still remains unclear, limiting the efficacy of clinical thermotherapy. 
Due to the limited quantity of iCSCs, particularly from patients in clinical treatment, it is 
impractical to perform molecular analysis using traditional analytical methods (e.g. LC-
MS). Therefore, techniques allowing for analysis at the single-cell level would provide a 
great advantage to study CSCs. Single-cell mass spectrometry (SCMS) analysis is a 
promising technique which can effectively utilize the limited resources of CSCs due to its 
high detection sensitivity and broad range of molecular analysis. 
           In this study, we applied the Single-probe SCMS technique [15-18] to explore the 
metabolic differences between drug-resistant cells and their parental cells at the single-
cell level, and to investigate the molecular mechanism at the emergence of drug 
resistance. Irinotecan, a widely used antitumor drug, was employed in this study to 
develop the early-stage drug resistant cell line, which were further used to measure their 
metabolomic features at the single-cell level. We discovered a new drug resistant 
mechanism, in which drug-resistant cells upregulate the expression of stearoyl-CoA 
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desaturase-1 (SCD1), resulting in the promoted cancer stemness and reactive oxygen 
species (ROS) level. This study can promote our understanding of how cancer cells 
develop resistance to anticancer drugs such as irinotecan, and potentially benefit early 
diagnosis of patients with drug-resistance and the development of novel therapeutic 
strategies. 
 
4.2 Methods  
4.2.1 Materials and Chemicals 
           Irinotecan was purchased from Life Technologies (Grand Island, NY, USA). The 
stock solution of irinotecan was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich, 
St. Louis, MO, USA) and further diluted into McCoy’s 5A cell culture medium (Life 
Technologies, Grand Island, NY, USA). The MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) was purchased from Biotium(Hayward, CA, USA). 
4.2.2 Cell lines and Cell culture 
           HCT-116 cells were originally obtained from American Type Culture Collection 
(ATCC) (Rockville, MD). The cells were cultured in McCoy’s 5A cell culture medium 
containing 10% FBS (fetal bovine serum; Life Technologies, Grand Island, NY, USA) 
and 1% Pen Strep (Life Technologies, Grand Island, NY, USA) at 37°C in an incubator 
with 5% CO2 supply (HeraCell, Heraeus, Germany). In order to obtain irinotecan-
resistant cells, we exposed the cells to a relatively high dose of irinotecan (1 µM) for 
different treatment time (i.e., ). Survived cells were then passaged at 80% confluence, and 
incubated at the same concentration of irinotecan. These processes were repeated until 
the resistant cell populations (i.e., 10- and 20-day resistant cells) were obtained.  
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4.2.3 Cytotoxicity assay 
         The MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) was 
used to determine the growth inhibitory effect of irinotecan on HCT-116 cell viability 
after 72 hr drug exposure. IC50 values were calculated by using Grahpad Prism software.  
4.2.4 Fabrication of the Single-probe 
        The fabrication process of the Single-probe has been described in previous 
studies.[17, 19] Briefly, there are three components in a Single-probe: a needle pulled 
from dual-bore quartz tubing (outer diameter (OD): 500 µm; inner diameter (ID): 127 µm, 
Friedrich & Dimmock, Inc., Millville, NJ, USA) using a laser pipet puller (P-2000 
micropipette puller, Sutter Instrument, Novato, CA, USA), a fused silica capillary (OD: 
105 µm; ID: 40 µm, Polymicro Technologies, Phoenix, AZ, USA), and a nano-ESI 
emitter produced using the same type of fused silica capillary. A Single-probe is 
fabricated by embedding a laser-pulled dual-bore quartz needle with a fused silica 
capillary and a nano-ESI emitter.   
4.2.5 The Single-probe SCMS Set-up 
               Irinotecan-resistant cells and parental cells were attached on the glass sides 
through over-night culture, and slides containing cells were placed onto a motorized 
XYZ−translation stage system. The stage system was controlled using a LabView 
software package. A syringe (250 µl; Hamilton Co., Reno, NV, USA) was used to 
continuously provide the sampling solvent (acetonitrile; Sigma-Aldrich St. Louis, MO, 
USA), and a stable liquid junction was formed at the Single-probe tip to extract cellular 
contents during the experiment. Using the microscope as a visual guide, the tip of the 
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Single-probe (OD ~10 µm) was precisely inserted into a targeted cell. Cellular contents 
were withdrawn towards the nano-ESI emitter through the capillary action and 
immediately ionized by a voltage applied on the conductive union followed by MS 
analysis using a Thermo LTQ Orbitrap XL mass spectrometer (Thermo Scientific, 
Waltham, MA, USA). Mass analysis parameters are listed as follows: mass range (m/z), 
200–1500; mass resolution, 60 000; ionization voltage at positive ion mode, +4.5 kV; 
microscan, 1; max injection time, 100 ms; AGC (automatic gain control) on. 
4.2.6 Data analysis 
             The pretreatment of SCMS data was performed prior to statistical analysis. 
SCMS data (m/z values with their relative intensities) were exported as tab-delimited data 
files using Thermo Xcalibur Qual Browser (Thermo Scientific, Waltham, MA, USA). 
Only relatively abundant peaks (intensity > 103) were exported, whereas background 
signals, such as peaks from solvent and cell culture medium, were subtracted from MS 
data. To minimize the influence induced by fluctuations of ion signals during 
experiments, ion intensities were normalized to the total ion current (TIC). We used 
Geena 2 online software to preform peak alignment. Student’s t-test (for data with equal 
variance) was then applied to obtain ions with significantly different abundance between 
two groups (p < 0.05). 
4.2.7 Western blot analysis 
                      Cell lysates were prepared using radioimmunoprecipitation assay (RIPA) 
buffer containing protease inhibitor (Thermo Scientific). Equal amount of proteins was 
separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membrane (GH, Healthcare Life Science). 
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Membrane was blocked by 10% non-fat milk (Bio-Rad) incubate overnight with primary 
antibody at 4°C. The following primary antibodies were used for Western blot: anti-
SCD1 antibody (Thermo Fisher Scientific) and anti-tubulin antibody (Abcam, UK). The 
corresponding secondary antibody (Thermo Fisher Scientific) was added during the 
incubation (1hr, at room temperature), and then membranes were washed using PBS 
buffer for three times. Finally, protein bands were vitalized using the Opti-4CN western 
blot detection kit (Bio-Rad). 
4.2.8 Flow cytometry analysis 
           The Stratedigm S1400Exi flow cytometer platform was used to determine the 
expression of cancer stem cell biomarker CD133 and CD24 in drug-resistant cells and 
parental cells. Briefly, cells were suspended in the solution containing 0.5% bovine 
serum albumin (BSA, Sigma-Aldrich, St. Louis) and antibodies (human anti-CD24-FITC 
and human anti-CD133-PE, Miltenyi Biotec) on ice. CD133 and CD24 double-positive 
cells (CD133+/CD24+) were gated using control cells that incubated with IgG1 isotype 
control FITC-conjugated antibody and PE-conjugated antibody (Biolegend, San Diego, 
CA).  
           For reactive oxygen species (ROS) detection, cells were incubated in McCoy’s 5A 
cell culture medium containing 1µM CM-H2DCFDA (Thermo Fisher Scientific) for 30 
min at 37 °C, and then washed with PBS buffer based on previous studies. Cells were 
analyzed using the Stratedigm S1400Exi flow cytometer platform. 
4.2.9 RNA extraction and Quantitative real-time polymerase chain reaction (qPCR) 
 The RNeasy Mini Kit (Qiagen, Valencia, CA) was used to isolate RNA from cells 
according to the manufacturer's instructions. The potential genomic DNA contaminants 
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were removed using a DNA-free™ DNA Removal Kit (Thermo Fisher Scientific). 
iScript™ Reverse Transcription Supermix (Bio-Rad Laboratories, CA) was used to 
synthesize the cDNA, and then qPCR experiments were performed using a Bio-Rad 
CFX96 Touch™ Real-Time PCR Detection System using SsoAdvanced™ Universal 
SYBR® Green Supermix (Bio-Rad).  
The sequences of the primers and annealing temperatures were as follows:  




CD24: (5’- TCCAAGGCACCCAGCATCCTGCTAGA-3’ and 5’-
TAGAAGACGTTTCTTGGCCTGAGTCT-3’), ALDH1A1: (5’- 
CGGGAAAAGCAATCTGAAGAGGG-3’ and 5’- 
GATGCGGCTATACAACACTGGC-3’) 
Actin: (5’- CGTCACCAACTGGGACGACA-3’ and 5’-
CTTCTCGCGGTTGGCCTTGG-3’)  
The relative expression of each gene was calculated using the ΔΔCT method with CFX 
manager software (Bio-Rad), and the target gene expression was normalized by the 
endogenous housekeeping gene β-actin. In addition, No-RT controls and No-template 






4.3.1 Irinotecan-resistant cells have higher abundance of unsaturated lipids and 
fatty acids than parental cells 
          Irinotecan resistant cells were established by exposure to irinotecan in cell culture 
medium for 3, 10 and 20 days. The drug resistance of each group of cells was determined 
by MTT viability assay for 72hr. As shown in Figure 4.1A, the MTT results indicated 
that parental cells were more sensitive to irinotecan compared to drug-treated cells with 
IC50 values of 3.0 µM, 5.3 µM, 7.8 µM and 11.0 µM. Previous studies demonstrated that 
the cell lines displaying two to eight folds resistance compared to parental cell lines could 
be considered as clinically relevant drug-resistant cells.[24] Therefore, based on the MTT 
test results, the cells treated with irinotecan for 10 days and 20 days are considered as 
drug-resistant cells. 
           In this study, our aim is to investigate the specific mechanism of cancer cells at the 
initial stage of irinotecan resistance, so cancer cells treated with irinotecan for 10days is 
our target. We compared the metabolic difference between irinotecan-resistant cells and 
parental cells based on the results obtained from single-probe mass spectrometry[20, 23, 
25, 26], and single-probe based metabolomics studies provided metabolic clues to study 
the mechanism of irinotecan resistance. We found that irinotecan-resistant cells have 
significant higher levels of multiple unsaturated lipids, including PC(33:4), PC(34:4), 
PC(38:5), PC(34:3), PC(35:1), PC(36:3), PC(34:2), PC(34:1) and PC(36:6)) (Figure 
4.1B). Moreover, four major fatty acids (C18:0 (stearic acid), C18:1 (oleic acid), C16:0 
(palmitic acid) and C16:1 (palmitoleic acid)) were also enriched in irinotecan-resistant 
cells compared to control cells (Figure 4.1C). In addition, the ratios of monounsaturated 
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fatty acids (MUFAs) to saturated fatty acids (SFAs), such as palmitic acid/palmitoleic 
acid (C16:0/C16:1) and stearic acid/oleic acid (C18:0/C18:1), were dramatically 
increased in irinotecan-resistant cells, as shown in Figure 4.1D. Taken together, the 
single-cell metabolomics suggests that irinotecan-resistant cells have a much higher level 
of unsaturated lipids and fatty acids than control cells. 
 
Figure 4.1     Irinotecan-resistant cells have high abundance of unsaturated lipids/fatty 
acids. (A) The IC50 of irinotecan against control, 3days, 10days and 20days treatment 
cells. (B) Relative abundances of fatty acids (C16:0, C16:1, C18:0, and C18:1) detected 
in drug-resistant cells and control cells. (C) Unsaturated lipids accumulated in irinotecan-
resistant cells. (D) Ratios of unsaturated fatty acid (UFA) to saturated fatty acid (SFA) in 






4.3.2 The high level of fatty acids/ lipids is mediated by SCD1 
           SCD1 is one of the most important desaturases that catalyzing SFAs to MUFAs, 
and the major products of SCD1 are oleic acid and palmitoleic acid.[27] Previous studies 
indicate that higher levels of unsaturated lipids and fatty acids are mainly produced by 
lipids desaturase SCD1 enzyme.[28] Therefore, we hypothesized that SCD1 induced the 
enrichment of unsaturated lipids and fatty acids in irinotecan-resistant cells. To 
investigate this hypothesis, we measured the SCD1 level through RT-PCR and western 
blotting, and SCD1 mRNA and protein levels were higher in irinotecan-resistant cells 
than in control cells (Figure 4.2A and 4.2B). Then we treated irinotecan-resistant cells 
with CAY10566, a specific inhibitor of SCD1[29], to further the study of functions of 
SCD1. CAY10566 significantly reduced the levels of multiple unsaturated lipids and 
dramatically suppressed the metabolic flux from SFAs to MUFAs (the ratios of 
C16:1/C16:0 and C18:1/C18:0) in irinotecan-resistant cells (Figure 4.2C-E). According 
to the result, SCD1 inhibitor altered the level of unsaturated lipids/ fatty acids in 
irinotecan-resistant cells, which is similar to the level in control cells. In conclusion, these 
results indicated that the high level of unsaturated lipids and fatty acids in irinotecan-
resistant cells were induced by SCD1. 
	 87	
 
Figure 4.2     SCD1 upregulated in drug-resistant cells and mediated the high level of 
unsaturated lipids. (A) RT-PCR measurement of SCD1 mRNA level in drug-resistant 
cells and control cells. (B) Western blot for SCD1 protein expression in drug-resistant 
cells and control cells. SCD1 inhibitor has significantly decreased expression of (C) 
unsaturated fatty acids, (D) ratio of MUFA/SFA and (E) unsaturated lipids. 
 
4.3.3 SCD1 modulates drug resistance in irinotecan-resistant cells  
           In order to investigate whether high SCD1 level played a role in the development 
of irinotecan resistance of colon cancer cells. We inhibited SCD1 activity by treating 
irinotecan-resistant cells with CAY10566 and the inhibition of SCD1 significantly 
reduced the resistance to irinotecan in drug-resistant cells, causing an around two-fold 
decrease of IC50 (Figure 4.3A). On the other hand, oleic acid is the major product of 
SCD1, and inhibiting the activity of SCD1 will apparently lead to a reduced production 
of oleic acid successfully rescued the cell viability under the treatment of CAY10566 
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(Figure 4.3B). Because oleic acid is an important product of ALDH1A1 inhibiting the 
activity of ALDH1A1 will apparently lead to a reduced production of RA. This 
consequence is likely related to the altered properties of CSCs such as the reduced 
stemness. It is reasonable to hypothesize that increasing RA supply during the cell culture 
will likely alleviate the inhibition by CM037. Taken together, SCD1 activity modulates 
the irinotecan resistance. 
 
Figure 4.3   SCD1 affected the drug resistance in irinotecan-resistant cells. (A) The IC50 
of control, irinotecan and irinotecan inhibitor treated groups against irinotecan. (B) Cell 
proliferation of HCT116 cells were measured under treatment of irinotecan, irinotecan 
inhibitor and oleic acid separately.  
 
4.3.4   Irinotecan treatment induced cancer stemness in irinotecan-resistant cells 
           Previous studies found that cancer therapy (e.g., radiochemotherapy and 
chemotherapy) could directly transform the non-stem cancer cells (NSCCs) into induced 
cancer stem cells (iCSCs), which contain relatively higher levels of SCD1 and 
unsaturated lipids. Moreover, iCSCs generally have high drug resistance compared to 
non-stem cancer cells. Therefore, we investigate whether SCD1 could induce the 
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stemness in irinotecan-resistant cells. We compared the lipid pattern among the control 
cells, irinotecan-resistant cells and CSCs. As shown in Figure 4A, the overall unsaturated 
lipids level in 10-day irinotecan-resistant cells and CSCs are higher than the levels in 
control cells. Likewise, major fatty acid levels, as well as the ratio of MUFAs/SFAs, in 
irinotecan-resistant cells were close to CSCs (Figure 4B and 4C). To further investigate 
the stemness of irinotecan-resistant cells, we measured the levels of three colon CSCs 
biomarkers (CD133, CD24, and ALDH1A1). The mRNA levels of ALDH1A1, CD133 
and CD24 were significantly increased in irinotecan-resistant cells compared to control 
cells (Figure 4D), and the enrichment of CD133 and CD24 in irinotecan-resistant cells 
also were also been confirmed by flow cytometry assay (Figure 4E and 4F).  Therefore, 
these results indicate that irinotecan-resistant cells acquired stemness.
 
Figure 4.4     Influence of irinotecan treatment on cancer stemness. 10-day irinotecan-
resistant cells possess similar metabolic features as the CSCs, including (A) levels of 
unsaturated fatty acids, (B) ratios of MUFA/SFA, and (C) levels of unsaturated lipids. 
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(D) RT-PCR measurements of mRNA levels of CD24, CD 133, CD ALDH1A1 in 10-day 
drug-resistant and control cells. Flow cytometry measurement of CD24 and CD133 CSC 
surface biomarkers in (E) control and (F) 10-day drug-resistant cells.  
4.3.5   SCD1 regulates the expression of cancer stem cell biomarker ALDH1A1 
Given that SCD1 are essential for the maintenance of stemness in CSCs[22], we 
investigated whether a high level of SCD1 could promote the development of stemness in 
irinotecan-resistant cells. We treated 10-day irinotecan-resistant cells with SCD1 
inhibitor (CAY10566), and results indicated that inhibiting SCD1 has no significant 
influence on the expression level of CD24 and CD133 in drug-resistant cells. However, 
interestingly, CAY10566 significantly reduced the mRNA level ALDH1A1. Moreover, 
oleic acid, the major product of SCD1, could successfully rescue the mRNA level of 
ALDH1A1 in 10-day irinotecan-resistant cells under CAY10566 treatment (Figure 4.5A). 
These results suggest that SCD1 specifically upregulates the expression of ALDH1A1, 
which potentially promotes the stemness development of IR cells.  
4.3.6 ALDH1A1 were associated to the reactive oxygen species (ROS) level in drug-
resistant cells 
           The function of ALDH1A1 is to catalyze oxidation of aldehydes, which 
contributes to the cellular detoxification, retinoic acid metabolism, and protection from 
reactive oxygen species (ROS)[24, 25]. Moreover, high level of ROS can induce 
oxidative stress and promote cell death in cancer cells. For example, multiple anticancer 
drugs can result in the enrichment of ROS to induce cell apoptosis[26, 27]. To further 
understand the role of ALDH1A1 in the irinotecan-resistant cells, we suppressed 
ALDH1A1 activity using its inhibitor (N, N-diethylaminobenzaldehyde, DEAB). As 
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shown in Figure 4.5B, the ROS level was significantly increased by DEAB in 10-day IR 
cells. In contrast, adding retinoic acid, which is a major product of ALDHIA1, drastically 
decreased the ROS level. Likewise, SCD1 inhibitor (CAY10566) also increased the ROS 
level in IR cells, whereas oleic acid (a major product of SCD1) rescued the inhibition 
(Figure 4.5B).  Our results indicate that in irinotecan-resistant cells contain overexpressed 
SCD1, which further results in upregulated ALDH1A1, promoted stemness, and 
decreased ROS level. All above factors contribute to increased drug resistance.
 
Figure 4.5     Influence of SCD1 on the expression of ALDH1A1 and the level of ROS. 
Measurements of (A) ALDH1A1 mRNA and (B) ROS of 10-day IR cells under different 
treatment conditions.  
 
4.4 Discussion 
           Irinotecan is a widely used antitumor drug to against multiple cancers, including 
brain cancer, breast cancer, lung cancer, and especially metastatic colon caner. 
Specifically, irinotecan is the first- or second-line treatment for metastatic colon 
cancer.[28-30] Irinotecan targets DNA topoisomerase I, and results in double–stand DNA 
breakage and finally causes cell death.[31-33] However, the clinical activity of irinotecan 
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is frequently limited by de novo or acquired clinical resistance.[34, 35] Previous studies 
found the chemoresistance of cancer cells is generally associated with metabolic 
reprogramming.[36-39]. For example, to escape from the irinotecan chemotoxity, cancer 
cells may require a large supply of metabolic substrates to access a series of defense 
activities through enhancing glycolysis and lipogenesis.[36, 40] For example, it has been 
reported lipid accumulation occurs in cancer cells with irinotecan treatment,[41] and de 
novo lipids synthesis enzymes were enriched in the irinotecan resistance cells. [42] 
However, it is still unknown how lipogenesis contributes to irinotecan resistance. 
The current study revealed a novel mechanism that irinotecan induces the activation of 
lipid desaturase SCD1, resulting in accumulations of unsaturated lipids/fatty acids. SCD1 
is one of the major lipid desaturases catalyzing the conversion of SFAs (e.g., stearic 
(C18:0) and palmitic acid (C16:0)) to MUFAs (e.g., oleic acid (C18: 1) and palmitoleic 
acid (C16: 1)) in mammalian cells. In addition, SCD1 stimulates the conversion of FAs 
into triglycerides, phospholipids, and cholesterol ester, which contribute to cell 
membrane synthesis during cell mitosis. However, little is known about the role of SCD1 
in irinotecan-resistant cells. Previous studies indicated that the inhibition of SCD1 
impacted cell growth and proliferation process, and overexpressed SCD1 facilitated 
tumor survival in liver, lung, and pancreatic cancers. Moreover, inhibiting SCD1 reverted 
the resistance to cisplatin and sorafenib in different types of CSCs such as lung, 
hepatocellular carcinomas, and ovarian CSCs. These studies implied the importance of 
SCD1 in chemoresistance. For the first time, we demonstrated the SCD1 could enhance 
the resistance to irinotecan in HCT-116 colon cancer cell line. 
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           Interestingly, we found irinotecan treatment produced drug-resistance cells 
possessing features of CSCs, i.e., overexpressed CSC biomarkers CD133, CD24, and 
ALDH1A1[43], compared with their parental cells. CSCs are a rare subset of cancer cells 
with the ability to self-renew, initiate tumors, and resistant chemotherapy.[44] In general, 
CSCs confers the resistance to traditional therapeutic methods through multiple ways, 
including entering a protective quiescent state, up-regulating the expression of ABC 
transporters, and decreasing ROS level.[45] Recent studies indicated that the ionizing 
radiotherapy could generate CSCs by dedifferentiation of NSCCs through up-regulated 
signaling pathways (e.g., Notch, Wnt, ect.).[13] Because SCD1 is an important 
intermediate in Wnt protein biogenesis[46], it is suggested as a key factor affecting 
cancer stemness and tumor initiation capacity in ovarian and colon CSCs.[18, 22] Our 
current study indicate that the levels of unsaturated lipids/fatty acids and the ratios of 
MUFA/SFA in irinotecan-resistant cells are comparable to those CSCs compared to 
parental cells. According to previous studies, the ratio of palmitic acid/palmitoleic acid 
(C16:0/C16:1) and stearic acid/oleic acid (C18:0/C18:1) reflect the expression and 
activity of SCD1 enzyme[47]. These results may suggest that SCD1 contributes to the 
development of cancer stemness in irinotecan-resistant cells. Thus, a better understanding 
of the potential role of SCD1 in the characteristics of irinotecan resistance cells, 
especially the development of cancer stemness, is of great significance for study the 
mechanism of irinotecan resistance. However, inhibiting the activity of SCD1 had no 
significant influence on the expression of CD133 and CD24, whereas the level of 
ALDH1A1 mRNA drastically decreased after treatment with CAY10566. In general, 
SCD1 specifically regulate the expression of ALDH1A1 rather than other CSCs 
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biomarkers. ALDH1A1 is a well-known CSCs biomarker[48, 49], and its major function 
is to oxidize retinal to retinoic acid (RA), which contributes to the cellular detoxification, 
retinoic acid metabolism, and protection from oxygen species (ROS) in CSCs[50]. 
Previous studies indicate that ROS belong to metabolomic byproducts of aerobic 
respiration, and they play essential roles to maintain redox homeostasis. Increased levels 
of ROS induce oxidative stress and DNA damage, and eventually lead cell death.[51] Our 
experimental results indicate that inhibiting the activity of ALDH1A1 and SCD1 can 
significantly increase the ROS level, suggesting SCD1 and ALDH1A1 can likely protect 
cancer cells from apoptosis by maintaining the level of ROS. 
           Our finding demonstrates that the irinotecan-resistant cells upregulate the 
expression of SCD1, and result in higher levels of unsaturated lipids/fatty acids, which 
can be potential biomarkers of drug resistance. In addition, SCD1 directly regulates the 
expression of ALDH1A1, a stem cell biomarker of colon cancer, and contributes to the 
generation of the CSCs. Moreover, ALDH1A1 protects cancer cells from irinotecan 
chemotherapy by decrease the level of ROS to avoid apoptosis. Given the important role 
of SCD1 in irinotecan-resistant cells, combining SCD1 inhibitors and irinotecan can be 
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Chapter 5     Microscale Mass Spectrometry Analysis of Extracellular 
Metabolites in Live Multicellular Tumor Spheroids 
 
5.1 Introduction 
      Cancer recurrence is one of the major threats for the health of patients receiving 
chemotherapy.[1, 2] For example, around 40% patients with breast cancers can develop 
recurrent metastatic diseases after chemotherapy.[3, 4] Recent studies indicate that central 
tumor cells play crucial roles in cancer recurrence.[5, 6] Due to the distribution gradients 
of oxygen, nutrients, and energy, tumors possess gradients of proliferation cells and 
metabolites abundances from outer to inner regions.[7-9] Generally, central tumor cells 
stop cell cycle progression and become dormant due to their microenvironment, while 
cells in outer regions of tumors have high proliferative activities.[5] Because cytostatic 
drugs mainly target proliferating cells, central cancer cells with low proliferating rate 
could survive from drug treatment and potentially cause the disease relapse after the 
therapy.[5, 6, 10] Previous studies found that extracellular compounds are critical in 
multiple biological behaviors of tumors,[11, 12] including tumor growth and progression, 
cell-cell communication, and cancer cell migration and metastasis.[13, 14] Studying 
extracellular compounds produced by central tumor cells can potentially identify more 
specific cancer biomarkers, reveal the characteristic responses of cancer cell under drug 
treatment, and provide guidelines for the amelioration of current cancer therapies. 
      Conventionally, two-dimensional (2D) cell monolayers are widely used for drug 
discovery studies.[15] However, results obtained from 2D cultured cells cannot be 
directly translated into in vivo settings because of their totally different microenvironment 
compared with cells in actual tissues. For example, the 2D cell monolayers are exposed to 
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sufficient oxygen and nutrients, whereas the microenvironment of cells in solid tumors 
contains gradients of oxygen, energy, and some critical chemicals.[16] Previous studies 
indicate that the extracellular compounds secreted by 2D-cultured cells are much less 
abundant than those in a three-dimensional (3D) environment, suggesting that 
interactions among cells in 2D models are different from those in 3D environment.[17] It 
is evident that, compared with 2D culture, 3D cell cultures can better mimic the 
microenvironment and cell-cell interactions of in vivo tumors.[18] The multicellular 
tumor spheroids (hereinafter referred to as spheroids) are widely used 3D tumor 
models.[19, 20] Spheroids have been proven to possess numerous characteristics similar 
to in vivo tumors, such as extracellular compounds and protein production patterns,[20, 
21] making them more accurate ideal models for the research of extracellular molecules. 
      However, studies of broad ranges of molecules inside live tumors have not been 
widely carried out due to the lack of appropriate analytical techniques. In a long time, the 
detection of extracellular biomolecules is limited by their low concentrations, especially 
once they diffuse into the cell culture medium or dilute in body fluid. Microdialysis 
devices, which use a semipermeable membrane to enrich molecules, have been utilized to 
study the extracellular compounds of tumors or tissues.[22-24] However, the general 
sizes of microdialysis probes range between 200 and 500 µm, with the smallest one 
around 200 µm,[25-27] resulting in limited spatial resolution. Therefore, it is very 
challenging to use these techniques to study relatively small targets such as spheroids 
(sizes are generally less than 1 mm),19-21 tumors at early stages, or small regions inside 
large tissues. In addition, lipophilic compounds may be retained by the tubing or other 
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probe components, resulting in a discrepancy of components sampling and low or no 
analyte recovery the amount of sample solution needed.[28, 29] 
      In this study, we developed a microscale device, the micro-funnel, to collect the 
extracellular molecules produced from cells in the central region of spheroids. The micro-
funnel has a small tip size (~25 µm), which allows it to be implanted into a live spheroid 
for direct collection of extracellular compounds without being diluted and selected. A 
Single-probe device is inserted into the orifice of the micro-funnel to extract the collected 
extracellular molecules for direct MS analysis. The Single-probe is a miniaturized 
multifunctional sampling and ionization device that can be coupled with MS for the real-
time microscale bioanalysis. The Single-probe MS techniques have been successfully 
used to study live single cells (single cell MS), and to map biomolecules on animal 
tissues (MS imaging) with high spatial resolutions.[30-34] Due to its extremely small 
sampling probe size (<10 µm) and high efficiency of extraction and ionization, the 
Single-probe is an ideal device to analyze small amounts of biomolecules collected in the 
micro-funnel device. By combining the micro-funnel with the Single-probe, we measured 
anticancer drug irinotecan and its major metabolites in the central region of spheroids, 
and determined their abundance changes under different treatment concentrations and 
time lengths. In addition, we investigated the influence of irinotecan treatment on the 
compositions of extracellular metabolites. Our study provides a new tool for the research 





5.2 Experimental section 
5.2.1 Fabricate the Single-probe and the micro-funnel 
      The detailed fabrication protocols of the Single-probe were provided in our 
previous work.[30, 34] Briefly, a Single-probe (Figure 5.1(a)) consists of three 
components: a dual-bore quartz tubing (outer diameter (OD) 500 µm; inner diameter (ID) 
127 µm, Friedrich & Dimmock, Inc., Millville, NJ, USA) pulled using a laser pipette 
puller (P-2000 micropipette puller, Sutter Instrument, Novato, CA, USA), a fused silica 
capillary (OD 105 µm; ID 40 µm, Polymicro Technologies, Phoenix, AZ, USA), and a 
nano-ESI emitter produced using the same type of fused silica capillary. A Single-probe is 
fabricated by embedding a laser-pulled dual-bore quartz needle with a fused silica 
capillary and a nano-ESI emitter.[30, 34] The micro-funnel (Figure 5.1(b)) is produced 
using a fused silica capillary (OD 360 µm; ID 70 µm, Polymicro Technologies, Phoenix, 
AZ, USA). Upon removing the coating material, the fused silica capillary is pulled using 
the laser pipette puller (tip size ~25 um), and cut into a micro-funnel with a desired 
length (~5 mm).  
5.2.2 Implant micro-funnels in spheroids 
      The colon carcinoma cell line HCT-116 was used as the model to culture spheroids. 
First, we cultured cells following the standard protocols. Cells were cultured in McCoy’s 
5A cell culture medium (Life Technologies, Grand Island, NY, USA) containing 10% 
FBS (fetal bovine serum; Life Technologies, Grand Island, NY, USA) and 1% Pen Strep 
(Life Technologies, Grand Island, NY, USA). A CO2 incubator (HeraCell, Heraeus, 
Germany) was used to culture cells under well-controlled conditions (5% CO2, 37 °C), 
and cell passage was performed every two days. Second, we cultured spheroids using 
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HCT-116 cells. The culture protocol of spheroids was generally adopted from previous 
studies with some modifications.[35-37] To foster the accumulation of cells and promote 
the success rate of culturing spheroids, agarose-coated 96-well plates (with U-bottom 
wells) were utilized in our modified protocols. Briefly, 60 µL of agarose gel (1.8 %; 
Sigma-Aldrich, St. Louis, MO, USA) was added into individual wells in a 96-well plate 
(U-bottom; VWR, Radnor, PA, USA). 200 µl of cell solution (containing ~12,000 cells) 
was added into the agarose-coated wells, and the micro-funnel was horizontally placed on 
the top of agarose coating with its tip positioned in the well center.  Because the fused 
silica is a biocompatible material,[38] cells incubated under normal conditions (5% CO2, 
37 °C) can attach to and grow around the micro-funnel tip. Culture medium was changed 
every 48 hours, and spheroids with implanted micro-funnels were collected after 14 days 
of culture. Using an inverted microscope, we selected the similar size (diameters ~1 mm) 
of spheroids, in which the micro-funnels tips were implanted in the center regions. Eight 
(n = 8) samples were used in each group for drug treatment and control experiments. The 
screening process and replicated measurements allow us to minimize the influence of 






























Figure 5.1     The combined micro-funnel and Single-probe technique for MS analysis of 
extracellular compounds in live spheroids. (a) A photo of a Single-probe device. (b) A 
photo of a micro-funnel before and after implanted into a spheroid. (c) Coupled micro-
funnel and Single-probe device. (d) Real-time MS analysis of extracellular compounds in 
a live spheroid using the coupled micro-funnel and Single-probe device. 
 
5.2.3 Drug treatment of spheroids  
        Irinotecan was purchased from Life Technologies (Grand Island, NY, USA). The 
stock solution of irinotecan was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich, 
St. Louis, MO, USA), and further diluted into McCoy’s 5A cell culture medium to 
prepare drug solutions with a series of concentrations. To perform drug treatment, a 
plastic microscope slide (VWR, Radnor, PA, USA) with a pinhole (diameter: ~360 um) 
was prepared and placed on the top a well in the 96-well plate (Figure 5.1(c)). The 
pinhole on the plastic slide was used to vertically hold the micro-funnel implanted into a 
spheroid. Irinotecan solutions were added into wells to submerge spheroid, whereas the 
orifice of the micro-funnel was retained above the treatment solution, eliminating any 
infusion of treatment solution into micro-funnels. We have conduced both concentration- 
and time-dependent studies. In the concentration-dependent experiments, spheroids were 
treated for 5 hrs using a series of concentrations (5, 20.6, 50, 100, 200, 300, 400, and 500 
µM). In time-dependent studies, we used the IC50 of irinotecan (20.6 uΜ)[39] and treated 
them for various lengths of time (5, 12, 24, and 48 hrs). Untreated spheroids were used as 
the control group in experiments. 
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5.2.4 Couple the Micro-funnel with the Single-probe MS setup 
      The extracellular contents collected in the micro-funnel present in a very small 
volume (~1.2 nL) that is challenging for conventional MS analysis. The Single-probe 
device, which is designed for microscale MS analysis, is appropriate for analysis of 
molecules collected in the micro-funnel. To conduct an experiment, the 96-well plates 
containing spheroids were placed on a home-built XYZ−translation stage system (Figure 
5.1(d)),[30, 34] and the spatial motion of the stage was controlled with the LabView 
software package.[40] Using the microscope as a visual guide, the tip of the Single-probe 
(OD ~10 µm) was precisely placed on the orifice of a micro-funnel (ID ~70 µm); a small 
gap between the Single-probe tip and micro-funnel orifice is present due to the size 
difference. The sampling solvent (acetonitrile; Sigma-Aldrich St. Louis, MO, USA) was 
continuously provided (~0.1µL/min) by a syringe (250 µl; Hamilton Co., Reno, NV, 
USA), and a liquid junction formed at the Single-probe tip performs a highly efficient 
extraction of extracellular contents collected inside the micro-funnel. The extracted 
molecular species were withdrawn by the nano-ESI emitter through the capillary action, 
and immediately ionized by a voltage applied on the conductive union followed by MS 
analysis using a Thermo LTQ Orbitrap XL mass spectrometer (Thermo Scientific, 
Waltham, MA, USA). Mass analyze parameters are listed as follows: mass range (m/z = 
200−1,500), mass resolution 60,000, +4 kV ionization voltage at positive ion mode, 1 
microscan, 100 ms max injection time, and AGC (automatic gain control) on. 
      Under the optimized conditions, stable ion signals can be obtained without having 
bubbles inside the emitter (i.e., solvent flow rate is too low) or solvent dripping on the 
Single-probe tip (i.e., solvent flow rate is too high). Due the gap between the Single-
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probe tip and micro-funnel orifice as well as the optimized flow rate, the sampling 
solvent is unlikely to be delivered into spheroids through the micro-funnel affecting cell 
growth environment. The solvent transport through diffusion is also negligible. A MS 
measurement of a spheroid is usually accomplished within 5 minutes, which is marginal 
compared with the time needed for acetonitrile molecules to diffuse through the micro-
funnel to reach cells (~1.2 hrs). The diffusion time can be estimated using t = x2/2D, in 
which x (5 mm) is the diffusion distance and D (1.445x10-5 cm2/s) is the diffusion 
coefficient of acetonitrile in water.  
5.2.5 Data processing 
       The molecular identification of irinotecan and its metabolites was performed by 
comparing their accurate m/z values with theoretical results. More confident analyses 
were carried by conducting tandem MS analysis (MS/MS or MS2, i.e. fragments analysis 
of selected ions) and comparing with results from the standard irinotecan sample and 
published work.[39, 41] However, a real biological tissue consists of complex 
histological structures and chemical components, and a large amount of information is 
present within each mass spectrum. Manual analysis of MS data can only provide the 
limited and selected information of species among numerous amounts of data. In contrast, 
statistical analysis methods, including Principle Component Analysis (PCA), t-test, and 
Analysis of Variance (ANOVA), are powerful tools to extract features from a complex 
MS data.[42-45] We utilized statistical data analysis methods to analyze MS results 
obtained from spheroids experiments. First, we export peaks (with m/z values and relative 
intensities) into Excel data format using Thermo Xcalibur Qual Browser (Thermo 
Scientific, Waltham, MA, USA). Due to the extremely complexed MS data, we only 
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export relatively abundant peaks (i.e., ion intensities higher than 104) for analysis; the 
background noise level is <103. To minimize the influence induced by fluctuations of ion 
signals during experiments, we used the relative ion intensities normalized to the total ion 
current (TIC). Second, we upload the Excel data onto online software Geena2 
(http://bioinformatics.hsanmartino.it/geena2/)[46] for peak alignment. Third, we import 
treated data into Metaboanalyst 3.0 
(http://www.metaboanalyst.ca/faces/ModuleView.xhtml)[47-55] to conduct statistical 
data analysis, including PCA and the t-test. PCA was utilized to detect the difference of 
chemical compositions between drug treated and control groups, whereas the t-test was 
applied to extract characteristic molecular peaks with significant abundance changes (P < 
0.05) upon drug treatment. Finally, we use online database METLIN 
(https://metlin.scripps.edu/metabo_batch.php)[56] and human metabolome database 
(HMDB; http://www.hmdb.ca)[57-59] to tentatively label all ions of interest, which can 
be grouped them into a few different major categories using the heat maps.  
 
5.3 Results and Discussions 
5.3.1 Detection of irinotecan and its metabolites  
Although the distribution of irinotecan and its metabolites in spheroids has recently been 
reported,[39, 60] the drug abundance change and the metabolites composition in the 
microenvironment inside a living tumor are still unclear. The combined micro-funnel and 
Single-probe design aims to collect and detect anticancer drugs, drug metabolites, and 
cell metabolites inside live spheroids. As shown in Figure 5.2, using our techniques we 
have successfully detected the drug compound and multiple drug metabolites, including 
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SN-38 (m/z 393.1437), hydroxyl-irinotecan (m/z 603.2802), decarboxyl-irinotecan (m/z 
543.2956), and dehydro-irinotecan (m/z 585.2697). MS/MS analysis has been performed 
to further confirm the structures of irinotecan and its metabolites accumulated by micro-
funnel. Irinotecan and its metabolites were not detected in tumors in the control group. 
 
 
Figure 5.2     Detection of irinotecan and its metabolites from extracellular compounds 
accumulated by the micro-funnel. 
          Irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy 
camptothecin) has been widely used in clinical treatment of colon cancer and lung 
cancer.[61] The metabolic pathways of irinotecan have already been reported,[39, 62] as 
partially summarized in Figure 5.3. Irinotecan is a pro-drug that can be metabolized by 
carboxylesterases into the active compound SN-38, a cytotoxic metabolite that is 300 to 
1000-fold more active than irinotecan.[41, 63-65] SN-38 can irreversible induced DNA 
damage by targeting Topoisomerase I and stabilizing the DNA cleavable complex, and 
result in cancer cell death.[66, 67] The detection of irinotecan from extracellular contents 
inside tumors is expected since the drug molecules can be delivered into inner regions 
through molecular diffusion.[8] The drug metabolite SN-38 detected in extracellular 
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environment is likely from the secretion of cancer cells.[68] Previous studies 
demonstrated that SN-38 can be expelled by colon cancer cells through efflux 
mechanism, which is directly related to their drug resistance capabilities.[69, 70] For 
example, P-glycoprotein (P-gp), an ATP-binding cassette transporter, has been considered 
as the major transporter of irinotecan and SN-38.[7, 69] Similarly, the multidrug 




Figure 5.3     Scheme of irinotecan metabolism in tumor cells. All metabolites were 
detected as the singly protonated species in our experiments. 
        Another interesting observation is that, for spheroids treated with irinotecan, the 
abundances of decarboxyl-irinotecan (m/z 543.2956) has a similar trend to that of 
irinotecan (Figure 5.4). Although decarboxylated species was regarded as one of 
irinotecan metabolites[39] (Figure 5.3), we have detected this compound (with ~1% 
relative ion intensities compared with irinotecan) in irinotecan water solutions (i.e., 5, 20, 
100, and 500 µM). It is plausible that decarboxyl-irinotecan is produced through the in-
source fragmentation of irinotecan parent ion. We further performed two types of 
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experiments to better represent the influence of matrix effect on the detection irinotecan 
and its metabolites. (a) We used spheroids (control group) to prepared cell lysate 
solutions containing irinotecan with the above concentrations. (b) We added irinotecan 
solutions (with the above concentrations) in the syringe, and inserted the Single-probe tip 
into the micro-funnel implanted in spheroids (control group) to conduct MS 
measurements. The relative ion intensities of decarboxyl-irinotecan are ~1 % compared 
with irinotecan in both types of experiments. However, this ratio ranges between 3% and 
20% in the spheroid experiments depending on the treatment conditions: higher 
concentration and longer treatment time lead to more abundant SN-38 (Figure 5.4). 
Therefore, it is very likely that the extracellular decarboxyl-irinotecan detected from 
spheroids is primarily from irinotecan metabolism.  
5.3.2 Abundance Change of extracellular irinotecan and its metabolites in 
concentration- and time-dependent experiments 
       In addition to the detection of molecules of interest inside live spheroids, we have 
investigated the abundance change of irinotecan and its metabolites under different 
treatment conditions.  We have conducted comprehensive studies of spheroids treated 
using a series of concentrations and different lengths of time. In concertation-dependent 
experiments, we treated spheroids (n = 8 for each treatment concentration and control 
groups) with irinotecan using a series of concentrations (5, 20.6, 50, 100, 200, 300, 400, 
and 500 µM) for 5 hrs. We measured the relative abundances, which were normalized to 
the TIC, of extracellular irinotecan and its metabolites. As shown in Figure 5.4(a), the ion 
intensities of irinotecan increase with higher drug concentrations for treatment. 
Hydroxyl-irinotecan and SN-38 started to appear inside tumors at relatively higher 
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treatment concentrations (i.e., 100 and 300 µM for hydroxyl-irinotecan and SN-38, 
respectively). All four major metabolites were detected from tumors treated with 500 µM 
irinotecan. 
 
Figure 5.4    Concentration- and time-dependent measurements of extracellular 
irinotecan and its metabolites in live spheroids.  (a) The normalized ion intensities of 
irinotecan and its metabolites measured from spheroids treated using 5, 20.6, 50, 100, 
200, 300, 400, and 500 µM irinotecan for 5 hrs. (b) The normalized intensities of 
irinotecan and its metabolites measured from spheroids treated for 5, 12, 24, and 48 hrs 
using the IC50 of irinotecan (20.6 µM). Results are the averaged values (with standard 
deviations) from eight replicates (n = 8) for each concentration and time length. 
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Figure 5.5   Principle component analysis (PCA) of mass spectra. (a) PCA results of 
culture medium (fresh medium, medium after spheroids culture (control), and medium 
after drug treatment (50 µM irinotecan)) and extracellular compounds in micro-funnels 
(spheroids from control and drug treated (50 µM irinotecan) groups). (b) PCA results of 
extracellular compounds in spheroids in concentrations-dependent experiments (20.6, 
300, and 500 µM). (c) PCA results of extracellular compounds in spheroids in time-
dependent experiments (5, 12, and 48 hrs). Results are reported from eight replicates (n = 
8) in each group, and each symbol represents an independent experiment.
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For time-dependent measurements, the adopted drug concentration was 20.6 µM, 
which is the IC50 of irinotecan for HCT-116 spheroids reported from previously 
studies.[39, 72] We treated spheroids (n = 8 for each treatment time) with 20.6 µM 
irinotecan for various lengths of time (5, 12, 24, 48, and 72 hrs). However, the 
treatment of 72 hrs resulted in a complete detachment of spheroids from micro-
funnels, the corresponding MS measurements were not conducted. In general, 
abundances of irinotecan and its metabolites as well as the number of drug 
metabolites increase along with longer treatment time (Figure 5.4(b)). For example, 
the hydroxyl-irinotecan and SN-38 were detected after 12 and 48 hrs, respectively; 
however, they were not observed from samples with shorter time drug treatments.  
        The combined micro-funnel and Single-probe device has been proven to 
successfully detect the extracellular drug and its metabolites in the central regions of 
spheroids treated under a variety of different conditions. Our techniques can be used 
to study the pharmacokinetics of drugs (such as the drug absorption and excretion) 
and the rate of drug metabolism inside live tumors. These techniques can potentially 
provide an effective approach to investigate the fundamentals of anti-drug ability of 
tumor cells, and facilitate the determination of appropriate drug concentration needed 
in drug screening studies.  
5.3.3 Influence of drug treatment on the extracellular metabolites inside 
spheroids  
      The molecular compositions of cell metabolites (including both intracellular and 
extracellular species) can rapidly response to the changes of cell status and the living 
environment. Previous analyses of cell metabolites from tissues are  
primarily conducted using cell lysate prepared from tissues. The corresponding 
experimental results cannot discriminate between intracellular and extracellular 
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metabolites of living tissues. This previously intractable task can be accomplished 
using the combined micro-funnel and Single-probe device.      Due to the critical roles 
of extracellular compounds on cell-cell communication and cancer cell migration and 
metastasis, we applied our techniques to investigate whether drug treatment can 
modulate the composition of extracellular compounds inside spheroids. 
      First, we demonstrated that compounds in culture medium have no interference 
with the analysis of molecules collected in the micro-funnels, although our 
experiments were designed to prohibit the infusion of culture medium into the micro-
funnel during the drug treatment (Figure 5.1(d)). We conducted PCA of mass spectra 
obtained from three medium groups (i.e., the fresh medium, medium collected after 
spheroids culture, and the medium collected after 50 µM irinotecan treatment) as well 
as samples collected in micro-funnels from irinotecan-treated spheroids and the 
control group (Figure 5.5(a)). PCA results indicate that the molecular compositions in 
culture media are significantly different from those extracellular compounds inside 
spheroids. In fact, culture medium is composed of inorganic salts, amino acids, 
vitamins, and glucose. In contrast, the major metabolites detected in tumor 
environments include phospholipids, glycerides, fatty acids, and glycoside deviates 
(please refer to Figure 5.6 for details). These results demonstrate that the micro-funnel 
device can effectively accumulate extracellular compounds in center regions of 
spheroids without having the leakage of culture medium.  
      Second, we investigated the general trends of composition change of 
extracellular compounds induced by drug treatment under different conditions. PCA 
results show that samples from different treatment concentrations (Figures 5.5(b)) and 
time lengths (Figures 5.5(c)) exhibit different metabolic signatures. Moreover, the 
data points are generally located farther away from the control groups, and their 
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distributions are broader for samples with higher concentrations (Figure 5.5(b)) or 
longer time (Figure 5.5(c)) for drug treatment. It is very likely that these trends are 
attributed to the metabolites change as cellular drug uptake increases, which are 
induced by higher drug concentration or longer time for treatment. Farther distance 
(i.e., higher scores on PCA plots) is due to the increased abundance of extracellular 
metabolites; broader distribution is likely associated with sample diversity (e.g. such 
as minor differences in size of spheroids and location of micro-funnel implant), and 
the caused variations in cell metabolite become more significant as the drug uptake 
increases. 
      Third, for a better understanding of cell metabolic regulation and the response of 
tumor cells to drug treatment, we classified the extracellular metabolites that are 
significantly altered by anticancer drug treatment based on t-test results. We 
tentatively assigned the extracellular compounds collected in micro-funnels by 
searching the measured accurate m/z values in METLIN and HMDB database (mass 
accuracy < 5 ppm). Because previous studies found that drug treatment affects the 
metabolism of the extracellular lipids,[73] we focused our current study on analyzing 
the irinotecan-induced extracellular lipid change. As summarized in the heat maps 
(Figures 5.6(a) and 5.6(b)), the patterns of extracellular lipids are different between 
control and irinotecan-treated tumors, and their compositions also change with the 
increase of drug concentration and treating time length. Specifically, lipids 
significantly changed by irinotecan treatment include phospholipids (phosphatidic 
acids (PAs), phosphoethanolamines (PEs), phosphatidylglycerols (PGs), 
phosphatidylserines (PSs), and phosphatidylinositols (PIs)), and glycerolipids 
(diglycerides (DGs) and triglycerides (TGs)). Although it is impractical to obtain the 
exact structure information of all tentatively assigned peaks, we can confidently 
119	
	
classify these species into different groups such as PA, PE, PG, PS, PI, DG, TG. In 
addition, our technology allows us to conduct MS2 analysis of ions of interest for 
more confident structure identification. For example, four compounds (i.e., DG 
(38:5), PC (34:5), PC (40:7), TG (50:3)) have been confirmed by performing MS2 
analysis and comparing our mass spectra with the METLIN database. MS3 and above 
analyses were not carried out due to inadequate ion intensities.  
 
Figure 5.6    Heat maps summarizing the categorized extracellular lipids measured 
from spheroids under different treatment conditions. The compositions of 
extracellular lipids were significant changed by anticancer drug treatment under (a) 
different concentrations (20.6, 300, and 500 µM) and (b) different treatment times (5, 
12, and 48 hrs). Results are reported from eight replicates (n = 8) in each group. PA 
(phosphatic acid), PE (phosphoethanolamine), PG (phosphatidylglycerol), PS 
(phosphatidylserine), PI (phosphatidylinositol), PC (phosphatidylcholine), MG 
(monoglycerides), DG (diglycerides), TG (triglyceride), SM (sphingomyelin). 
       Previously studies found that some colorectal cancer cells can develop 
resistance to the SN-38 through regulating their cellular metabolism.[74, 75] For 
example, under irinotecan treatment, colon cancer cells can enhance de novo 
lipogenesis to accumulate cellular TGs and phospholipids, which can promote cell 
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cells for energy storage; phospholipids are essential components for biological 
membrane, and they are also found as second messengers for transduction of 
intercellular signals.[80-82] Both TGs and phospholipids are critical for cell 
proliferation and apoptosis.[83-85] The enhanced lipogenesis in drug-treated cells can 
increase lipids secretion and result in increased concentrations of extracellular 
lipids.[79] Correspondingly, in our live spheroids studies, we did observe the increase 
of extracellular lipids (e.g., phospholipids, TGs, and DGs) under irinotecan treatment 
(Figures 5.6(a) and 5.6(b)), which was likely attributed to the trigged drug resistance 
of cancer cells inside central regions of tumors. Detailed interpretation of more MS 
data is needed to better understand other significant implications, which potentially 
present in our experimental results, of cancer biology and anticancer drug 
mechanisms; however, this goal is beyond the scope of current study. 
 
5.4 Conclusion 
We reported a study of using combined microscale devices, the micro-funnel and 
the Single-probe, to collect extracellular contents inside live spheroids for real-time 
MS analysis. The micro-funnel is produced from laser-pulled fused silica capillary, a 
biocompatible material, with small tip size (~25 µm). This type of microscale device 
can be implanted into live spheroids cultured from cancer cells to collect the 
extracellular compounds in inner region of spheroids. The spheroids were treated 
using anticancer drug irinotecan under a series of conditions. The collected 
extracellular contents in the micro-funnel were then efficiently extracted by the 
Single-probe, a microscale sampling and ionization device, for real-time MS analysis. 
We successfully detected irinotecan, drug metabolites, and cellular metabolites using 
our technologies. Statistical data analyses, including PCA and t-test, have been carried 
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out to obtain the overall feathers of cell metabolomic changes induced by anticancer 
drug treatment. Our results indicate that extracellular compounds in inner tumor 
regions are significantly altered by irinotecan treatment, and different treatment 
conditions result in significant differences in metabolic signatures. In particular, the 
increased abundances of phospholipids and glycerolipids reflect cellular responses to 
drug treatment, and may indicate the drug resistance of central tumor cells. Our 
current study demonstrates that the combined micro-funnel and Single-probe MS 
technique can be used to monitor extracellular metabolites in the microenvironment 
inside spheroids.  However, we may not be able to completely eliminate the 
possibility of sampling intracellular molecules in experiments. Dead cells (e.g., due to 
the lack of oxygen and nutrients as well as the present of drug molecules) may be 
present inside spheroids. Cellular contents released by dead cells can be mixed with 
extracellular metabolites and collected by the micro-funnel in MS measurements. 
Future studies are necessary to test this possibility. This novel technique can be 
potentially applied to studies of live tissues in different areas, including fundamental 
research of the regulation of extracellular compounds in tumor development, drug 
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